Original Article
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
N Engl J Med 1999; 340:1144-1153April 15, 1999
- Abstract
Background and Methods
On behalf of the Gynecologic Oncology Group, we performed a randomized trial of radiotherapy in combination with three concurrent chemotherapy regimens — cisplatin alone; cisplatin, fluorouracil, and hydroxyurea; and hydroxyurea alone — in patients with locally advanced cervical cancer. Women with primary untreated invasive squamous-cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix of stage IIB, III, or IVA, without involvement of the para-aortic lymph nodes, were enrolled. The patients had to have a leukocyte count of at least 3000 per cubic millimeter, a platelet count of at least 100,000 per cubic millimeter, a serum creatinine level no higher than 2 mg per deciliter (177 μmol per liter), and adequate hepatic function. All patients received external-beam radiotherapy according to a strict protocol. Patients were randomly assigned to receive one of three chemotherapy regimens: 40 mg of cisplatin per square meter of body-surface area per week for six weeks (group 1); 50 mg of cisplatin per square meter on days 1 and 29, followed by 4 g of fluorouracil per square meter given as a 96-hour infusion on days 1 and 29, and 2 g of oral hydroxyurea per square meter twice weekly for six weeks (group 2); or 3 g of oral hydroxyurea per square meter twice weekly for six weeks (group 3).
Results
The analysis included 526 women. The median duration of follow-up was 35 months. Both groups that received cisplatin had a higher rate of progression-free survival than the group that received hydroxyurea alone (P<0.001 for both comparisons). The relative risks of progression of disease or death were 0.57 (95 percent confidence interval, 0.42 to 0.78) in group 1 and 0.55 (95 percent confidence interval, 0.40 to 0.75) in group 2, as compared with group 3. The overall survival rate was significantly higher in groups 1 and 2 than in group 3, with relative risks of death of 0.61 (95 percent confidence interval, 0.44 to 0.85) and 0.58 (95 percent confidence interval, 0.41 to 0.81), respectively.
Conclusions
Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival among women with locally advanced cervical cancer.
Media in This Article
Figure 2
Kaplan–Meier Estimates of Overall Survival.Figure 1
Kaplan–Meier Estimates of Progression-free Survival.Article Activity
- Article
Cervical cancer is the second most frequent cancer among women worldwide and the most frequent cancer among women in Africa, Asia, and South America.1 In the United States, where screening for cervical cancer is readily available, most women who are found to have cervical cancer were not screened regularly.2 As a result, about 25 percent of patients with cervical cancer in the United States present with locally advanced disease (stage IIB through IVA according to the staging system of the International Federation of Gynecology and Obstetrics).3,4
The ability of radiotherapy to cure locally advanced cervical cancer is limited by the size of the tumor, because the doses required to treat large tumors exceed the limit of toxicity in normal tissue.5 Efforts to overcome this problem have included the use of large-particle radiotherapy, the use of different radiation-fractionation schedules, and the concurrent use of hyperthermia or chemotherapy.
Theoretically, chemotherapy and radiotherapy could have a synergistic effect; for example, the chemotherapy might increase the sensitivity of the tumor to radiation. Moreover, radiotherapy could be used for local disease while chemotherapy is used for systemic disease.6 Concurrent chemotherapy inhibits the repair of sublethal damage from radiation, synchronizes cells to a particularly radiosensitive phase of the cell cycle, and is cytotoxic in vitro.7-9 The concurrent use of single-drug and multiple-drug regimens with radiotherapy has been tested in women with cervical cancer, but combination therapy has not gained wide acceptance.10
The Gynecologic Oncology Group has performed several prospective, randomized studies of the effect of concurrent chemotherapy and radiotherapy in women with locally advanced cervical cancer. Radiotherapy combined with treatment with hydroxyurea has been compared in separate trials with radiotherapy alone, with radiotherapy and concomitant therapy with misonidazole, and with radiotherapy and concomitant treatment with cisplatin and fluorouracil11-13 (and Whitney CW: unpublished data). As compared with radiotherapy alone, treatment with hydroxyurea and radiotherapy significantly increased the rate of complete response, progression-free survival, and overall survival.11 As compared with treatment with misonidazole and radiotherapy, treatment with hydroxyurea and radiotherapy increased progression-free survival and was less toxic.12,13 However, treatment with cisplatin, fluorouracil, and radiotherapy resulted in greater improvement in progression-free survival and overall survival than did treatment with hydroxyurea and radiotherapy (Whitney CW: unpublished data).
At the time we were developing the protocol used in the current study, radiotherapy plus concomitant chemotherapy with hydroxyurea was the standard combined-therapy regimen for advanced cervical cancer, because an early analysis of the combination of radiation, cisplatin, and fluorouracil failed to show improved progression-free survival. However, myelosuppression is a limiting toxic effect of treatment with hydroxyurea, whereas cisplatin is less myelosuppressive and can be given weekly during radiotherapy, with acceptable levels of toxicity.14-17 In our study, to improve the efficacy of the cisplatin and fluorouracil combination, we added hydroxyurea to the regimen, because of evidence that this drug inhibits ribonucleotide reductase and depletes tumor cells of deoxyuridine monophosphate.18 The depletion of deoxyuridine monophosphate may be important because this compound competes with the active metabolite of fluorouracil, fluorodeoxyuridine monophosphate, for the binding of thymidylate synthase. In addition, the responses in phase 2 trials of this chemotherapy regimen with radiotherapy in patients with cervical cancer and in patients with head and neck cancer were favorable.19,20 Therefore, we undertook a randomized study in which all women with locally advanced cervical cancer received local radiation as well as weekly concomitant treatment with cisplatin alone; the combination of cisplatin, fluorouracil, and hydroxyurea; or hydroxyurea alone.
Methods
Eligibility
The institutions that participated in the study are listed in the Appendix. Women with untreated invasive squamous-cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix of International Federation of Gynecology and Obstetrics stage IIB (localized disease with parametrial involvement), stage III (extension of the tumor to the pelvic wall), or stage IVB (involvement of the bladder or rectal mucosa) were enrolled in the study from April 1992 to April 1997. All cancers were confirmed histologically by the Gynecologic Oncology Group pathology committee. Patients with disease outside the pelvis and those with metastasis to para-aortic lymph nodes or intraperitoneal disease were not eligible.
Each patient was required to undergo a complete physical examination, a pelvic examination under anesthesia, chest radiography, and intravenous pyelography or abdominal computed tomography to determine the clinical stage of the cancer. In addition, patients were required to have undergone a specific type of extraperitoneal para-aortic lymphadenectomy.21 Patients were required to have a Gynecologic Oncology Group performance status of 0, 1, 2, or 3 (equivalent to Karnofsky performance scores of 90 or 100, 70 or 80, 50 or 60, and 30 or 40, respectively) and to have no history of other cancers.
Other eligibility criteria were as follows: a leukocyte count of at least 3000 per cubic millimeter, a platelet count of at least 100,000 per cubic millimeter, a serum creatinine level of no more than 2.0 mg per deciliter (177 μmol per liter), a serum bilirubin level that was no more than 1.5 times the upper limit of normal at the institution where it was measured, and a serum aspartate aminotransferase level that was no more than 3 times the upper limit of normal at the institution where it was measured. Additional pretreatment evaluations included assessment of performance status and measurements of the cervical tumor and serum electrolytes and magnesium. All patients gave written informed consent according to institutional, state, and federal regulations.
Radiotherapy
Radiotherapy was administered to the whole pelvic region in 24 fractions totaling 40.8 Gy or 30 fractions totaling 51.0 Gy, followed one to three weeks later by intracavitary brachytherapy (the insertion of a radioactive implant). Either one or two intracavitary implants were inserted. The total dose delivered was 40 Gy in patients with stage IIB and 30 Gy in patients with stage III or IVA disease. The total dose delivered to point A (a reference location 2 cm lateral and 2 cm superior to the cervical os) was 80.8 Gy in patients with stage IIB and 81.0 Gy in patients with stage III or IVA disease; the total dose delivered to point B (the pelvic wall) was 55.0 Gy in patients with stage IIB disease and 60.0 Gy in patients with stage III or IVA disease. Pelvic radiation was delivered by anteroposterior and posteroanterior parallel ports or a four-field box technique (anteroposterior, posteroanterior, and two lateral fields) with an x-ray energy of at least 4-MV photons. The pelvic field extended from the upper margin of L5 to the midportion of the obturator foramen or the lowest level of disease, with a 3-cm margin, and laterally 1.5 to 2 cm beyond the lateral margins of the bony pelvic wall (at least 7 cm from the midline). For the lateral fields, the anterior border was the anterior border of the pubic symphysis and the posterior border was the space between S2 and S3. The fields could be modified to include areas of known tumor.
If two intracavitary applications were used, the second was to be given within two weeks after the first implant. If intracavitary brachytherapy could not be delivered, the tumor was treated with additional external-beam radiotherapy, for a total dose of 61.2 Gy. Interstitial and high-dose brachytherapy were not allowed.
The duration of the radiotherapy was 10 weeks. Radiotherapy was withheld if a patient had a leukocyte count of less than 2000 per cubic millimeter, and delays of up to one week were also allowed in the event of radiation-related gastrointestinal or genitourinary toxicity. The length of delays in radiotherapy, in days, was calculated by subtracting the planned duration of radiotherapy (the number of prescribed fractions plus 2 weekend days for every five fractions plus 10 days for each implant) from the actual duration of radiotherapy. The Radiological Physics Center in Houston reviewed all technical aspects of radiotherapy and verified the calibration of the instruments used.
Chemotherapy
The patients were randomly assigned to receive one of three chemotherapy regimens, which were given concomitantly with external-beam radiotherapy (Table 1Table 1
Chemotherapy Schedules and Dose Modifications.). Treatment with hydroxyurea or fluorouracil was discontinued if the leukocyte count dropped below 3000 per cubic millimeter or the platelet count dropped below 100,000 per cubic millimeter, and it was resumed once the counts rose above these levels. Treatment with cisplatin was discontinued if the leukocyte count dropped below 2500 per cubic millimeter or the platelet count dropped below 50,000 per cubic millimeter, and it was resumed once the counts rose above these levels. Adverse effects that required modifications in the doses in subsequent cycles are shown in Table 1.Statistical Analysis
The primary end points were survival and progression-free survival. Progression was defined as a 50 percent increase in the product of the two largest diameters of the primary tumor or metastasis. Progression-free survival was calculated from the date of entry into the study to the date of the first physical or radiographic evidence of disease progression, death, or the last follow-up visit. Survival was calculated from the date of entry into the study to the date of death or the last follow-up visit.
We calculated the target sample size of 165 patients for each regimen on the basis of an ability to detect a 35 percent decrease in the rate of disease progression with the use of either radiotherapy combined with treatment with cisplatin or radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea. The design called for final analysis when disease progression (or death) had occurred in 104 patients receiving the control regimen (radiotherapy combined with treatment with hydroxyurea). This design provided the study with a statistical power of 80 percent with the use of the log-rank test at an alpha level of 0.025 (by one-tailed test).22 At the time of this analysis 104 patients had had progression of disease in the control group and 89 patients had died, with or without disease progression — 86 percent of the number of deaths needed for a final analysis of survival. Thus, because of the large difference in outcome among the treatment groups and the similarity between the rates of survival and progression-free survival within each of the treatment groups, this analysis is the final analysis of survival and progression-free survival.
Randomization was carried out by a block arrangement; the treatment assignments were stratified according to center and the three clinical stages of disease, with approximately equal numbers assigned to each treatment group. Life-table estimates were calculated according to the method of Kaplan and Meier,23 and differences in progression-free survival were evaluated with use of the log-rank test according to the intention-to-treat principle.24 The Cox model was used to adjust for prognostic factors and to estimate the relative likelihood (and 95 percent confidence intervals) of survival and progression-free survival.25 Pearson's chi-square test was used to detect differences in the incidence of adverse effects among treatment regimens.26 All reported P values are two-tailed unless otherwise stated.
Interim analyses were conducted in May 1994, November 1995, and November 1996 with the use of prespecified critical values (11.1, 10.6, and 10.6, respectively) for the log-rank test with two degrees of freedom. The performance of these interim tests raised the type I error by only 0.05 percent. Because of this negligible increase and to simplify the presentation, the P values were not adjusted for the results of the interim analyses.
Results
Characteristics of the Patients
From April 1992 to April 1997, 575 patients were enrolled: 192 were assigned to receive radiotherapy and concomitant chemotherapy with cisplatin; 191 were assigned to receive radiotherapy and concomitant chemotherapy with cisplatin, fluorouracil, and hydroxyurea; and 192 were assigned to receive radiotherapy and concomitant chemotherapy with hydroxyurea. Forty-nine of these patients (9 percent) were subsequently found to be ineligible for the following reasons: because of deviations from the surgical protocol for the evaluation of para-aortic lymph nodes (44 patients), ineligible stage of disease (2), metastasis to para-aortic lymph nodes (1), incorrect primary diagnosis (1), and incomplete pretreatment testing (1). Thus, a total of 526 patients were included in the analysis: 176 in the group given radiotherapy combined with cisplatin therapy; 173 in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea; and 177 in the group given radiotherapy combined with hydroxyurea therapy.
There were no significant differences in the clinical characteristics among the three treatment groups (Table 2Table 2
Characteristics of the Patients.). The analyses reported here were performed in December 1998.Progression-Free Survival
The relative risk of progression of disease or death was 0.57 (95 percent confidence interval, 0.42 to 0.78) in the group given radiotherapy combined with cisplatin therapy and 0.55 (95 percent confidence interval, 0.40 to 0.75) in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea, as compared with the group given radiotherapy combined with hydroxyurea therapy, after adjustment for the clinical stage of disease. Patients who received the platinum-based regimens had significantly longer progression-free survival than those who received hydroxyurea (P<0.001 for both comparisons) (Figure 1Figure 1
Kaplan–Meier Estimates of Progression-free Survival.). A multiple regression analysis of progression-free survival was performed that included the prognostic variables identified by Stehman et al.27: clinical stage of disease, tumor size as assessed by physical examination, status of pelvic lymph nodes, age at diagnosis, and performance status. After adjustment for these five factors, the relative risks of disease progression for the group given radiotherapy combined with cisplatin therapy and the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea were extremely close (relative risks, 0.58 and 0.55, respectively) to the estimates obtained after adjustment for clinical stage of disease alone. The rates of progression-free survival at 24 months were 67 percent in the group given radiotherapy combined with cisplatin therapy; 64 percent in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea; and 47 percent in the group given radiotherapy combined with hydroxyurea therapy.Survival
The median duration of follow-up was 35 months. As of this writing, 75 percent of the patients have either died or have been followed for 30 months. A total of 205 patients have died (39 percent): 59 in the group given radiotherapy combined with cisplatin therapy; 57 in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea; and 89 in the group given radiotherapy combined with hydroxyurea therapy. After adjustment for the clinical stage of disease, the relative risk of death was 0.61 (95 percent confidence interval, 0.44 to 0.85) in the group given radiotherapy combined with cisplatin therapy and 0.58 (95 percent confidence interval, 0.41 to 0.81) in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea, as compared with the group given radiotherapy combined with hydroxyurea therapy. Survival rates were also significantly better in these two groups (P=0.004 and P=0.002, respectively) than in the group given radiotherapy combined with hydroxyurea therapy (Figure 2Figure 2
Kaplan–Meier Estimates of Overall Survival.). A multivariate analysis of survival that was adjusted for the five prognostic factors identified by Stehman et al. yielded essentially identical estimates of relative risks.Site of Progression
Patients in the group given radiotherapy combined with cisplatin therapy and the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea had less local progression (19 percent and 20 percent, respectively) than those in the group given radiotherapy combined with hydroxyurea therapy (30 percent). Patients in the two cisplatin-treated groups also had a lower frequency of lung metastases (3 percent and 4 percent, respectively) than patients treated with hydroxyurea alone (10 percent).
Chemotherapy
Table 3Table 3
Number of Cycles of Chemotherapy Received in Each Group. shows the number of cycles of chemotherapy (i.e., weeks) administered in each group.Radiotherapy
Eight patients did not receive any radiation therapy, and 41 (8 percent) received only external-beam treatment, but these 49 patients were evenly distributed among the three treatment groups. The number of patients who received within 15 percent of the prescribed total dose to both point A (69 to 93 Gy) and point B (stage IIB, 47 to 63 Gy; stage III or IVA, 51 to 59 Gy) was 159 (90 percent) in the group given radiotherapy combined with cisplatin therapy; 147 (85 percent) in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea; and 149 (84 percent) in the group given radiotherapy combined with hydroxyurea therapy.
The median duration of treatment was 9.0 weeks (10th and 90th percentiles, 7.1 and 11.9, respectively) in the group given radiotherapy combined with cisplatin therapy; 9.3 weeks (10th and 90th percentiles, 7.6 and 11.6) in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea; and 8.9 weeks (10th and 90th percentiles, 7.2 and 11.2) in the group given radiotherapy combined with hydroxyurea therapy. The median delay in administering radiotherapy was computed for the 455 patients who received doses within 15 percent of the prescribed dose to both points A and B. The median delay was 8 days (the 10th percentile was a time 2 days ahead of schedule, and the 90th percentile was a delay of 22 days) in the group given radiotherapy combined with cisplatin therapy; 10 days (10th and 90th percentiles, 1 and 26) in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea; and 8 days (10th and 90th percentiles, 1 day ahead of schedule and a delay of 23 days) in the group given radiotherapy combined with hydroxyurea therapy.
Adverse Effects
There were no treatment-related deaths. The types and frequencies of adverse effects are shown in Table 4Table 4
Adverse Effects.. The highest combined frequency of grade 3 (moderate) and grade 4 (severe) adverse effects was associated with treatment with radiotherapy and the three-drug regimen; the frequency in the other two groups was similar. The frequencies of both grade 3 and grade 4 leukopenia in the group given radiotherapy combined with treatment with cisplatin, fluorouracil, and hydroxyurea were more than double the frequencies in the other two groups (P<0.001). The frequencies of other hematologic effects of both grade 3 and grade 4 — predominantly granulocytopenia — in the group given radiotherapy combined with cisplatin, fluorouracil, and hydroxyurea therapy were approximately double those in the other two groups (P<0.001).Discussion
Pelvic radiotherapy by itself fails to control the progression of cervical cancer in 35 to 90 percent of patients with locally advanced disease. Despite improvements in radiation equipment and techniques, in approximately two thirds of the cases, progression occurs within the area that was irradiated.28,29 Thus, locoregional control must be improved. Since the para-aortic lymph nodes are often the first site of extrapelvic disease and involvement of these nodes was the most important prognostic factor in prior Gynecologic Oncology Group trials, only patients without involvement of the para-aortic lymph nodes were included in our study.27
We found higher rates of survival and progression-free survival among patients who were treated with radiotherapy and either cisplatin alone or cisplatin, fluorouracil, and hydroxyurea than among patients who were treated with radiotherapy and hydroxyurea alone. Cisplatin is believed to augment the effects of radiation by inhibiting the repair of radiation-induced sublethal damage and by sensitizing hypoxic cells to radiation.9,30 Because of its cytotoxic effect, the drug reduces the bulk of tumors, which leads to reoxygenation of the tumor and entry of the cells into a radiation-sensitive phase of the cell cycle. In a study of 19 human cervical-cancer cell lines, Britten et al. found that radiotherapy and concomitant treatment with cisplatin increased the rates of death of these tumor cells.31 However, radiosensitivity was increased in only four cell lines, suggesting that the effect of this combined therapy is primarily caused by direct cytotoxicity. The effects of chemotherapy should not interfere with the planned course of radiation, and one advantage of cisplatin is that it has limited adverse effects on bone marrow. In our study, the rate of local recurrences was significantly lower with either cisplatin-based regimen than with the hydroxyurea regimen, whereas the rate of distant recurrences, specifically in the lungs, was only slightly less. These results suggest that the principal effect of cisplatin is radiosensitization.
The effect of radiotherapy with concomitant treatment with cisplatin alone has been studied in several phase 2 trials.16,18,32-40 Two trials reported improvements in local control of tumors and survival in patients with invasive bladder cancer and in patients with non–small-cell lung cancer.41,42 However, in a small study of 45 patients with cervical cancer, radiotherapy and chemotherapy with cisplatin (25 mg per square meter per week) increased the rate of local control by 35 percent (P<0.025 for the comparison with radiotherapy alone), but there was no long-term improvement in survival.14,43
Many combinations of cisplatin have been studied in phase 2 trials of patients with cervical cancer.44-51 In a phase 3 trial conducted by the Gynecologic Oncology Group, 388 patients were randomly assigned to receive radiotherapy and concomitant chemotherapy either with cisplatin and fluorouracil or with hydroxyurea (Whitney CW: unpublished data); the two-drug regimen improved survival (relative risk of death, 0.74; 95 percent confidence interval, 0.58 to 0.95). In the phase 3 study by Morris et al.,52 whose results are reported in this issue of the Journal, radiotherapy in combination with treatment with cisplatin and fluorouracil significantly improved the rates of disease-free survival and overall survival among women with stage IB through IVA cervical cancer.
The ability of carboplatin, which is a less toxic analogue of platinum than cisplatin, to act as a chemosensitizer has been assessed in patients with many kinds of tumors.53-59 Although cisplatin and carboplatin are often used interchangeably, we cannot assume that the results of our study also apply to treatment with carboplatin.
Hematologic toxicity was the principal adverse effect in this trial. The frequencies of grades 3 and 4 leukopenia were significantly higher with the three-drug combination than with the two single-drug regimens. Nevertheless, there were no significant differences in the length of radiotherapy among the three groups. Souhami et al. used radiotherapy concurrently with treatment with cisplatin, followed by high-dose brachytherapy, to treat 50 patients with cervical cancer.39 They found a high rate of response, but 28 percent of their patients had severe late gastrointestinal complications. Closer analysis of this study showed a dose-dependent effect of the brachytherapy on late rectal complications.60 Adverse urologic effects have occurred in mice treated with radiotherapy and chemotherapy with cisplatin,61 but increased rates of urologic complications were not observed in our study.
The radiation protocol that we used allowed a total dose of 81 Gy to be delivered to point A and anticipated a total treatment time of 10 weeks. Several studies have suggested that the total length of treatment influences the efficacy of radiotherapy.62-64 In our study, the duration of radiotherapy and the dose of radiation were similar among the three regimens, implying that the differences in progression-free survival and survival were related to the chemotherapy.
Our results demonstrate the superiority of radiotherapy and chemotherapy either with cisplatin alone or with cisplatin, fluorouracil, and hydroxyurea in patients with locally advanced cervical cancer (stage IIB, III, or IVA without metastasis to the para-aortic lymph nodes). Treatment with cisplatin alone was less toxic than treatment with the three-drug regimen. We recommend cisplatin as the standard drug for radiotherapy and chemotherapy for locally advanced cervical cancer.
Supported by grants from the National Cancer Institute (CA 27469 to the Gynecologic Oncology Group Administrative Office and CA 37517 to the Gynecologic Oncology Group Statistical Office).
We are indebted to the Radiological Physics Center for ensuring that the radiation doses delivered to all patients in this study were clinically similar; for reviewing all technical aspects of the treatment, verifying the reported doses, and participating in the clinical evaluation of all patients; and for monitoring the calibration of the dosimeters used at all participating institutions and for on-site evaluations of selected institutions as needed.
Source Information
From the Division of Gynecologic Oncology, Department of Reproductive Biology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland (P.G.R.); the Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, N.Y. (B.N.B.); the Radiation Oncology Service, Walter Reed Army Medical Center, Washington, D.C. (E.B.W.); the Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson (J.T.T.); the Division of Gynecologic Oncology, Hutzel Hospital and Wayne State University, Detroit (G.D.); the Division of Gynecologic Oncology, State University of New York Health Science Center at Brooklyn, Brooklyn (M.A.M.); the Division of Gynecologic Oncology, Duke University School of Medicine, Durham, N.C. (D.L.C.-P.); and the Department of Pathology, University of Washington, Seattle, and the Department of Pathology, Multicare Medical Center, Tacoma, Wash. (S.I.).
Address reprint requests to Denise Mackey at the GOG Administrative Office, Suite 1945, 1234 Market St., Philadelphia, PA 19107, or at dmackey@acog.org.
Appendix
The following Gynecologic Oncology Group institutions participated in the study: University of Alabama at Birmingham, Oregon Health Sciences University, Duke University Medical Center, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, Wayne State University School of Medicine, University of Minnesota Medical School, Emory University Clinic, University of Southern California Medical Center at Los Angeles, University of Mississippi Medical Center, Colorado Foundation for Medical Care, University of California Medical Center at Los Angeles, University of Washington Medical Center, Hospital of the University of Pennsylvania, University of Miami School of Medicine, Milton S. Hershey School of Medicine of Pennsylvania State University, Georgetown University Hospital, University of Cincinnati College of Medicine, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Health Science Center at Dallas, Indiana University Medical Center, Bowman Gray School of Medicine of Wake Forest University, Albany Medical College of Union University, University of California Medical Center at Irvine, Tufts–New England Medical Center, Rush–Presbyterian–St. Luke's Medical Center, State University of New York Downstate Medical Center, University of Kentucky, Eastern Virginia Medical School, Cleveland Clinic Foundation, Johns Hopkins Oncology Center, State University of New York at Stony Brook, Pennsylvania Hospital, Cooper Hospital University Medical Center, Columbus Cancer Council, University of Massachusetts Medical Center, Fox Chase Cancer Center, Medical University of South Carolina, Women's Cancer Center, University of Oklahoma Health Science Center, University of Chicago, University of Arizona Health Science Center, Tacoma General Hospital, Mayo Clinic, Case Western Reserve University, Tampa Bay Cancer Consortium, and New York Hospital–Cornell Medical Center.
- References
References
1
Parkin DM ,Pisani P ,Ferlay J . Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606
CrossRef | Web of Science | Medline2
Janerich DT ,Hadjimichael O ,Schwartz PE , et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health 1995;85:791-794
CrossRef | Web of Science | Medline3
SEER cancer incidence public use data base, 1973–1994. Bethesda, Md.: National Cancer Institute, 1997 (software).
4
Cervical cancer. NIH consensus statement. Vol. 14. No. 1. Bethesda, Md.: NIH Office of Medical Applications of Research, 1996:15-6.
5
Fletcher GH . Clinical dose-response curves of human malignant epithelial tumours. Br J Radiol 1973;46:1-12
CrossRef | Web of Science | Medline6
Steel GG ,Peckham MJ . Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91
Web of Science | Medline7
Sinclair WK . The combined effect of hydroxyurea and x-rays on Chinese hamster cells in vitro. Cancer Res 1968;28:198-206
Web of Science | Medline8
Phillips RA ,Tolmach LJ . Repair of potentially lethal damage in x-irradiated HeLa cells. Radiat Res 1966;29:413-432
CrossRef | Web of Science | Medline9
Fu KK . Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer 1985;55:Suppl:2123-2130
CrossRef | Web of Science | Medline10
Rose PG . Locally advanced cervical carcinoma: the role of chemoradiation. Semin Oncol 1994;21:47-53
Web of Science | Medline11
Hreshchyshyn MM ,Aron BS ,Boronow RC ,Franklin EW III ,Shingleton HM ,Blessing JA . Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 1979;5:317-322
CrossRef | Web of Science | Medline12
Stehman FB ,Bundy BN ,Keys H ,Currie JL ,Mortel R ,Creasman WT . A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix: a preliminary report of a Gynecologic Oncology Group study. Am J Obstet Gynecol 1988;159:87-94
Web of Science | Medline13
Stehman FB ,Bundy BN ,Thomas G , et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 1993;11:1523-1528
Web of Science | Medline14
Choo YC ,Choy TK ,Wong LC ,Ma HK . Potentiation of radiotherapy by cis-dichlorodiammine platinum (II) in advanced cervical carcinoma. Gynecol Oncol 1986;23:94-100
CrossRef | Web of Science | Medline15
Monyak DJ, Twiggs LB, Potish RA, et al. Tolerance and preliminary results of simultaneous therapy with radiation and cisplatin for advanced cervical cancer. In: Conference on the interaction of radiation therapy and chemotherapy. NCI monographs. No. 6. Washington, D.C.: Government Printing Office, 1988:369-73. (NIH publication no. 88-2939.)
16
Piver MS ,Lele SB ,Malfetano JH . cis-Diamminedichloroplatinum II based combination chemotherapy for the control of extensive paraaortic lymph node metastasis in cervical cancer. Gynecol Oncol 1987;26:71-76
CrossRef | Web of Science | Medline17
Malfetano J ,Keys H ,Kredentser D ,Cunningham M ,Kotlove D ,Weiss L . Weekly cisplatin and radical radiation therapy for advanced, recurrent, and poor prognosis cervical carcinoma. Cancer 1993;71:3703-3706
CrossRef | Web of Science | Medline18
Moran RG ,Danenberg PV ,Heidelberger C . Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem Pharmacol 1982;31:2929-2935
CrossRef | Web of Science | Medline19
Stehman FB ,Bundy BN ,Kucera PR ,Deppe G ,Reddy S ,O'Connor DM . Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I-II trial of the Gynecologic Oncology Group. Gynecol Oncol 1997;66:262-267
CrossRef | Web of Science | Medline20
Haraf DJ ,Vokes EE ,Weichselbaum RR ,Panje WR . Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope 1992;102:630-636
CrossRef | Web of Science | Medline21
Weiser EB ,Bundy BN ,Hoskins WJ , et al. Extraperitoneal versus transperitoneal selective paraaortic lymphadenectomy in the pretreatment surgical staging of advanced cervical carcinoma (a Gynecologic Oncology Group study). Gynecol Oncol 1989;33:283-289
CrossRef | Web of Science | Medline22
Schoenfeld DA . Sample-size formula for the proportional-hazards regression model. Biometrics 1983;39:499-503
CrossRef | Web of Science | Medline23
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science24
Mantel N . Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline25
Cox DR . Regression model and life-tables. J R Stat Soc [B] 1972;34:187-22026
Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames: Iowa State University Press, 1967.
27
Stehman FB ,Bundy BN ,DiSaia PJ ,Keys HM ,Larson JE ,Fowler WC . Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991;67:2776-2785
CrossRef | Web of Science | Medline28
Jampolis S ,Andras EJ ,Fletcher GH . Analysis of sites and causes of failures of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology 1975;115:681-685
Web of Science | Medline29
Lanciano RM ,Won M ,Coia LR ,Hanks GE . Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 Patterns of Care studies. Int J Radiat Oncol Biol Phys 1991;20:667-676
CrossRef | Web of Science | Medline30
Douple EB, Richmond RC. A review of interactions between platinum coordination complexes and ionizing radiation: implications for cancer therapy. In: Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin: current status and new developments. New York: Academic Press, 1980:125-47.
31
Britten RA ,Evans AJ ,Allalunis-Turner MJ ,Pearcey RG . Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys 1996;34:367-374
CrossRef | Web of Science | Medline32
Forastiere AA . Cisplatin and radiotherapy in the management of locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1993;27:465-470
CrossRef | Web of Science | Medline33
Bachaud JM ,Chatelut E ,Canal P , et al. Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I study. Am J Clin Oncol 1997;20:1-5
CrossRef | Web of Science | Medline34
Al-Sarraf M ,Pajak TF ,Marcial VA , et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. Cancer 1987;59:259-265
CrossRef | Web of Science | Medline35
Bedini AV ,Tavecchio L ,Milani F , et al. Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma: a feasibility study. Cancer 1991;67:357-362
CrossRef | Web of Science | Medline36
Eapen L ,Stewart D ,Danjoux C , et al. Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer. J Clin Oncol 1989;7:230-235
Web of Science | Medline37
Fields AL ,Anderson PS ,Goldberg GL , et al. Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 1996;61:416-422
CrossRef | Web of Science | Medline38
Coughlin CT. Clinical experience with high-dose cisplatin and radiation for treatment of epithelial malignancies. In: Conference on the interaction of radiation therapy and chemotherapy. NCI monographs. No. 6. Washington, D.C.: Government Printing Office, 1988:365-7. (NIH publication no. 88-2939.)
39
Souhami L ,Seymour R ,Roman TN , et al. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. J Radiat Oncol Biol Phys 1993;27:871-878
CrossRef | Web of Science | Medline40
Rettenmaier MA ,Moran MF ,Ramsinghani NF , et al. Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin. Cancer 1988;61:1301-1303
CrossRef | Web of Science | Medline41
Coppin CML ,Gospodarowicz MK ,James K , et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 1996;14:2901-2907
Web of Science | Medline42
Schaake-Koning C ,van den Bogaert W ,Dalesio O , et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530
Full Text | Web of Science | Medline43
Wong LC ,Choo YC ,Choy D ,Sham JST ,Ma HK . Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol Oncol 1989;35:159-163
CrossRef | Web of Science | Medline44
Kuske RR ,Perez CA ,Grigsby PW , et al. Phase I/II study of definitive radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) for advanced and recurrent gynecologic malignancies. Am J Clin Oncol 1989;12:467-473
CrossRef | Web of Science | Medline45
Roberts WS ,Kavanagh JJ ,Greenberg H , et al. Concomitant radiation therapy and chemotherapy in the treatment of advanced squamous carcinoma of the lower female genital tract. Gynecol Oncol 1989;34:183-186
CrossRef | Web of Science | Medline46
Heaton D ,Yordan E ,Reddy S , et al. Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy. Gynecol Oncol 1990;38:323-327
CrossRef | Web of Science | Medline47
Malviya VK ,Deppe G ,Kim Y ,Gove N . Concurrent radiation therapy, cis-platinum, and mitomycin C in patients with poor prognosis cancer of the cervix: a pilot study. Am J Clin Oncol 1989;12:434-437
CrossRef | Web of Science | Medline48
Malviya VK ,Han I ,Deppe G , et al. High-dose-rate afterloading brachytherapy, external radiation therapy, and combination chemotherapy in poor-prognosis cancer of the cervix. Gynecol Oncol 1991;42:233-238
CrossRef | Web of Science | Medline49
Brenner DE ,Gillette AW ,Jones HW III ,Burnett LS ,Malcolm AW . Simultaneous radiation and chemotherapy for advanced carcinoma of the cervix. Gynecol Oncol 1987;26:381-385
CrossRef | Web of Science | Medline50
Chang HC ,Lai CH ,Chen MS ,Chao AS ,Chen LH ,Soong YK . Preliminary results of concurrent radiotherapy and chemotherapy with cis-platinum, vincristine, and bleomycin in bulky, advanced cervical carcinoma: a pilot study. Gynecol Oncol 1992;44:182-188
CrossRef | Web of Science | Medline51
Lin J ,Ho ES ,Jan JS ,Yang CH ,Liu PS . High complete response rate of concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1996;61:101-108
CrossRef | Web of Science | Medline52
Morris M ,Eifel PJ ,Lu J , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143
Full Text | Web of Science | Medline53
Jacobs MC ,Eisenberger M ,Oh MC , et al. Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck: a phase I-II study. Int J Radiat Oncol Biol Phys 1989;17:361-363
CrossRef | Web of Science | Medline54
Zamboglou N ,Achterrath W ,Schnabel T ,Lenaz L ,Kolotas C ,Schmitt G . Simultaneous radiotherapy and chemotherapy with carboplatin in inoperable squamous cell carcinoma of the head and neck: a phase II study. Cancer Invest 1992;10:349-355
CrossRef | Web of Science | Medline55
Kunitoh H ,Watanabe K ,Nagatomo A ,Okamoto H ,Kimbara K . Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1997;37:103-109
CrossRef | Web of Science | Medline56
Ball D ,Bishop J ,Smith J , et al. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients. Int J Radiat Oncol Biol Phys 1995;31:267-272
CrossRef | Web of Science | Medline57
Corn BW ,Hernandez E ,Anderson L ,Fein DA ,Dunton CJ ,Heller P . Phase I/II study of concomitant irradiation and carboplatin for locally advanced carcinoma of the uterine cervix: an interim report. Am J Clin Oncol 1996;19:317-321
CrossRef | Web of Science | Medline58
Muderspach LI ,Curtin JP ,Roman LD , et al. Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study. Gynecol Oncol 1997;65:336-342
CrossRef | Web of Science | Medline59
Ausili-Cefaro G ,Marmiroli L ,Nardone L ,Salvi G . Prolonged continuous infusion of carboplatin and concomitant radiotherapy in advanced head and neck cancer: a phase I study. Am J Clin Oncol 1995;18:273-276
CrossRef | Web of Science | Medline60
Clark BG ,Souhami L ,Roman TN ,Evans MDC ,Pla C . Rectal complications in patients with carcinoma of the cervix treated with concomitant cisplatin and external beam irradiation with high dose rate brachytherapy: a dosimetric analysis. Int J Radiat Oncol Biol Phys 1994;28:1243-1250
CrossRef | Web of Science | Medline61
Lundbeck F ,Oussoren Y ,Stewart FA . Early and late damage in the mouse bladder after radiation combined with cyclophosphamide or cisplatinum, evaluated by two different functional assays. Acta Oncol 1993;32:679-687
CrossRef | Web of Science | Medline62
Lanciano RM ,Pajak TF ,Martz K ,Hanks GE . The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a Patterns-of-Care study. Int J Radiat Oncol Biol Phys 1993;25:391-397
CrossRef | Web of Science | Medline63
Girinsky T ,Rey A ,Roche B , et al. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:1051-1056
CrossRef | Web of Science | Medline64
Perez CA ,Grigsby PW ,Castro-Vita H ,Lockett MA . Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:1275-1288
CrossRef | Web of Science | Medline
- Citing Articles (595)
Citing Articles
1
Tetsuo Nonaka, Yuko Nakayama, Nobutaka Mizoguchi, Ryo Onose, Hisamori Kato, Hiroki Nakayama. (2012) Definitive radiation therapy for invasive carcinoma of the vagina: impact of high-dose rate intracavitary brachytherapy. International Journal of Clinical Oncology
CrossRef2
Rehan Khan, Abdul Quaiyoom Khan, Wajhul Qamar, Abdul Lateef, Farrah Ali, Muneeb U. Rehman, Mir Tahir, Swati Sharma, Sarwat Sultana. (2012) Chrysin abrogates cisplatin-induced oxidative stress, p53 expression, goblet cell disintegration and apoptotic responses in the jejunum of Wistar rats. British Journal of Nutrition1-12
CrossRef3
Mingzhu Yin, Haiyu Zhang, Huiyan Li, Xia Li, Yunduo Liu, Xiuwei Chen, Ge Lou, Kang Li. (2012) The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. Journal of Surgical Oncology 105:2, 206-211
CrossRef4
Won-Moo Lee, Sang-Il Park, Beob-Jong Kim, Moon-Hong Kim, Seok-Cheol Choi, Eui-Don Lee, Sang-Young Ryu. (2012) Clinicopathologic factors for central recurrence in patients with locally advanced bulky cervical cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology
CrossRef5
Marjorie Jenkins, Maurizio Chiriva-Internati, Leonardo Mirandola, Catherine Tonroy, Sean S. Tedjarati, Nicole Davis, Nicholas D'Cunha, Lukman Tijani, Fred Hardwick, Diane Nguyen, W. Martin Kast, Everardo Cobos. (2012) Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach. International Reviews of Immunology 31:1, 3-21
CrossRef6
B. Wörmann. (2012) Systemische Therapie in einem kurativen multimodalen Konzept. Der Onkologe
CrossRef7
Akila N. Viswanathan, Jennifer Moughan, William Small, Charles Levenback, Revathy Iyer, Sharon Hymes, Adam P. Dicker, Brigitte Miller, Beth Erickson, David K. Gaffney. (2012) The Quality of Cervical Cancer Brachytherapy Implantation and the Impact on Local Recurrence and Disease-Free Survival in Radiation Therapy Oncology Group Prospective Trials 0116 and 0128. International Journal of Gynecological Cancer 22:1, 123-131
CrossRef8
Sushil Beriwal, D. Jeffrey Demanes, Beth Erickson, Ellen Jones, Jennifer F. De Los Santos, Robert A. Cormack, Catheryn Yashar, Jason J. Rownd, Akila N. Viswanathan. (2012) American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. Brachytherapy 11:1, 68-75
CrossRef9
Akila N. Viswanathan, Bruce Thomadsen. (2012) American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles. Brachytherapy 11:1, 33-46
CrossRef10
Brent S. Rose, Yun Liang, Steven K. Lau, Lindsay G. Jensen, Catheryn M. Yashar, Carl K. Hoh, Loren K. Mell. (2012) Correlation Between Radiation Dose to 18F-FDG-PET Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Cervical Cancer Patients Treated with Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics
CrossRef11
Natsuo Tomita, Takafumi Toita, Takeshi Kodaira, Atsunori Shinoda, Takashi Uno, Hodaka Numasaki, Teruki Teshima, Michihide Mitsumori. (2012) Patterns of Radiotherapy Practice for Patients with Cervical Cancer in Japan, 2003–2005: Changing Trends in the Pattern of Care Process. International Journal of Radiation Oncology*Biology*Physics
CrossRef12
Kanyarat Katanyoo, Sompol Sanguanrungsirikul, Sumonmal Manusirivithaya. (2012) Comparison of Treatment Outcomes between Squamous Cell Carcinoma and Adenocarcinoma in Locally Advanced Cervical Cancer. Gynecologic Oncology
CrossRef13
Dong Hoon Suh, Kidong Kim, Jae Weon Kim. (2012) Major clinical research advances in gynecologic cancer in 2011. Journal of Gynecologic Oncology 23:1, 53
CrossRef14
Vijaya Galic, Thomas J. Herzog, Sharyn N. Lewin, Alfred I. Neugut, William M. Burke, Yu-Shiang Lu, Dawn L. Hershman, Jason D. Wright. (2012) Prognostic Significance of Adenocarcinoma Histology in Women with Cervical Cancer. Gynecologic Oncology
CrossRef15
Jie Tang, Yanxiang Tang, Jun Yang, Si Huang. (2012) Chemoradiation and Adjuvant Chemotherapy in advanced cervical adenocarcinoma. Gynecologic Oncology
CrossRef16
Kanyarat Katanyoo, Siriwan Tangjitgamol, Marisa Chongthanakorn, Thanatip Tantivatana, Sumonmal Manusirivithaya, Kanisa Rongsriyam, Atchima Cholpaisal. (2011) Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecologic Oncology 123:3, 571-576
CrossRef17
Xue-lian Du, Jiang Tao, Xiu-gui Sheng, Chun-hua Lu, Hao Yu, Cong Wang, Qu-qing Song, Qing-shui Li, Chun-xia Pan. (2011) Intensity-modulated radiation therapy for advanced cervical cancer: An comparison of dosimetric and clinical outcomes with conventional radiotherapy. Gynecologic Oncology
CrossRef18
Akila N. Viswanathan. (2011) Advances in the Use of Radiation for Gynecologic Cancers. Hematology/Oncology Clinics of North America
CrossRef19
Jeanne Carter, Richard Penson, Richard Barakat, Lari Wenzel. (2011) Contemporary Quality of Life Issues Affecting Gynecologic Cancer Survivors. Hematology/Oncology Clinics of North America
CrossRef20
Peter G. Rose, Michael W. Sill, D. Scott McMeekin, Amina Ahmed, Ritu Salani, S. Diane Yamada, Aaron Wolfson, Nancy Fusco, Paula M. Fracasso. (2011) A Phase I Study of Concurrent Weekly Topotecan and Cisplatin Chemotherapy with Whole Pelvic Radiation Therapy in Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology
CrossRef21
Arunkumar Anandharaj, Senthilkumar Cinghu, Won-Dong Kim, Jae-Ran Yu, Woo-Yoon Park. (2011) Fused Toes Homolog modulates radiation cytotoxicity in uterine cervical cancer cells. Molecular Biology Reports 38:8, 5361-5370
CrossRef22
Sang-Young Ryu, Won-Moo Lee, Kidong Kim, Sang-Il Park, Beob-Jong Kim, Moon-Hong Kim, Seok-Cheol Choi, Chul-Koo Cho, Byung-Ho Nam, Eui-Don Lee. (2011) Randomized Clinical Trial of Weekly vs. Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Locally Advanced Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 81:4, e577-e581
CrossRef23
Sarah M. McGuire, Yusuf Menda, Laura L. Boles Ponto, Brandie Gross, John Buatti, John E. Bayouth. (2011) 3’-deoxy-3’-[18F]fluorothymidine PET Quantification of Bone Marrow Response to Radiation Dose. International Journal of Radiation Oncology*Biology*Physics 81:3, 888-893
CrossRef24
Atsuko Ishikawa, Tomo Suga, Yoshimi Shoji, Shingo Kato, Tatsuya Ohno, Hitoshi Ishikawa, Shinji Yoshinaga, Kiyoshi Ohara, Hisanori Ariga, Kuninori Nomura, Yuta Shibamoto, Ken-Ichi Ishikawa, Takashi Moritake, Yuichi Michikawa, Mayumi Iwakawa, Takashi Imai. (2011) Genetic Variants of NPAT-ATM and AURKA are Associated With an Early Adverse Reaction in the Gastrointestinal Tract of Patients With Cervical Cancer Treated With Pelvic Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 81:4, 1144-1152
CrossRef25
Israel Fernandez-Pineda, Sheri L. Spunt, Lalit Parida, Matthew J. Krasin, Andrew M. Davidoff, Bhaskar N. Rao. (2011) Vaginal tumors in childhood: the experience of St. Jude Children's Research Hospital. Journal of Pediatric Surgery 46:11, 2071-2075
CrossRef26
J. Leseur, A. Devillers, D. Williaume, E. Le Prisé, C. Fougerou, C. Bouriel, J. Levêque, E. Monpetit, J. Blanchot, R. de Crevoisier, E. Garin. (2011) Tomographie par émission de positons au (18F)-fluorodésoxyglucose dans les cancers du col utérin : évaluation ganglionnaire et valeur pronostique/prédictive des données de la tumeur primitive. Cancer/Radiothérapie
CrossRef27
Julie K. Schwarz, Barry A. Siegel, Farrokh Dehdashti, Perry W. Grigsby. (2011) Metabolic Response on Posttherapy FDG-PET Predicts Patterns of Failure After Radiotherapy for Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef28
Sanghyuk Song, Changhoon Song, Hak Jae Kim, Hong-Gyun Wu, Jin Ho Kim, Noh-Hyun Park, Yong-Sang Song, Jae Weon Kim, Soon-Beom Kang, Sung W. Ha. (2011) 20year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: Impact of treatment period and concurrent chemotherapy. Gynecologic Oncology
CrossRef29
Yoo-Young Lee, Chel Hun Choi, Chang Ohk Sung, In-Gu Do, SeungJae Huh, Taejong Song, Min Kyu Kim, Ha-Jeong Kim, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae. (2011) Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag level. Gynecologic Oncology
CrossRef30
Laura K. Hart, Mildred I. Freel, Pam J. Haylock, Susan K. Lutgendorf. (2011) The Use of Healing Touch in Integrative Oncology. Clinical Journal of Oncology Nursing 15:5, 519-525
CrossRef31
Mandy S. Y. Lung, Wendy M. Mak, Vincent Murray. (2011) The use of a human papillomavirus 18 promoter for tissue-specific expression in cervical carcinoma cells. Cellular & Molecular Biology Letters 16:3, 477-492
CrossRef32
Gabriela Studer, Michelle Brown, Eveline Barata Salgueiro, Hildegard Schmückle, Natalie Romancuk, Gisela Winkler, Soon Jae Lee, Ariane Sträuli, Beatrix Kissling, Reinhard Dummer, Christoph Glanzmann. (2011) Grade 3/4 Dermatitis in Head and Neck Cancer Patients Treated With Concurrent Cetuximab and IMRT. International Journal of Radiation Oncology*Biology*Physics 81:1, 110-117
CrossRef33
Yong Jung Song, Joo-Young Kim, Su-Kyoung Lee, Hyun-Sun Lim, Myong Cheol Lim, Sang-Soo Seo, Sokbom Kang, Dong Ock Lee, Sang-Yoon Park. (2011) Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer. International Journal of Cancer 129:4, 896-902
CrossRef34
Wen Zhang, Jia Sheng, Zhen Huang. 2011. Structures and Functions of Nucleic Acids Modified With S, Se, and Te and Complexed with Small Molecules. , 101-141.
CrossRef35
José Pérez-Regadera, Alfonso Sánchez-Muñoz, Javier De-la-Cruz, Claudio Ballestín, David Lora, Rosa García-Martín, Amalia Sotoca, Elisabeth Pérez-Ruiz, Eduardo Lanzós. (2011) Impact of Epidermal Growth Factor Receptor Expression on Disease-Free Survival and Rate of Pelvic Relapse in Patients With Advanced Cancer of the Cervix Treated With Chemoradiotherapy. American Journal of Clinical Oncology 34:4, 395-400
CrossRef36
Michael D. Hasselle, Brent S. Rose, Joel D. Kochanski, Sameer K. Nath, Rounak Bafana, Catheryn M. Yashar, Yasmin Hasan, John C. Roeske, Arno J. Mundt, Loren K. Mell. (2011) Clinical Outcomes of Intensity-Modulated Pelvic Radiation Therapy for Carcinoma of the Cervix. International Journal of Radiation Oncology*Biology*Physics 80:5, 1436-1445
CrossRef37
Tana S. Pradhan, Haiou Duan, Evangelia Katsoulakis, Ghadir Salame, Yi-Chun Lee, Ovadia Abulafia. (2011) Hydronephrosis as a Prognostic Indicator of Survival in Advanced Cervix Cancer. International Journal of Gynecological Cancer 21:6, 1091-1096
CrossRef38
Jonas van de Lande, Silvia von Mensdorff-Pouilly, Roelof G. Lettinga, Jurgen M. Piek, Rene H.M. Verheijen. (2011) Open Versus Laparoscopic Pelvic Lymph Node Dissection in Early Stage Cervical Cancer. International Journal of Gynecological Cancer1
CrossRef39
Chien-Chih Chen, Jin-Ching Lin, Jian-Sheng Jan, Shih-Chu Ho, Lily Wang. (2011) Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecologic Oncology 122:1, 9-13
CrossRef40
Richard Pötter, Petra Georg, Johannes C.A. Dimopoulos, Magdalena Grimm, Daniel Berger, Nicole Nesvacil, Dietmar Georg, Maximilian P. Schmid, Alexander Reinthaller, Alina Sturdza, Christian Kirisits. (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiotherapy and Oncology 100:1, 116-123
CrossRef41
Abhirami Hallock, Kathleen Surry, Deidre Batchelar, Lauren VanderSpek, Jasper Yuen, Alex Hammond, John Radwan, Brian Yaremko, George Rodrigues, David D'Souza. (2011) An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: A single institution experience. Practical Radiation Oncology 1:3, 173-181
CrossRef42
Olivier M. Niemoeller, Claus Belka. (2011) Radiotherapy and TRAIL for cancer therapy. Cancer Letters
CrossRef43
Susan Davidson. (2011) Treatment for advanced cervical cancer: Impact on quality of life. Critical Reviews in Oncology/Hematology 79:1, 24-30
CrossRef44
Fidel A. Valea. 2011. Cervical Carcinoma. , 297-328.
CrossRef45
Silvia Rodríguez Villalba, Carmen Díaz-Caneja Planell, José Manuel Cervera Grau. (2011) Current opinion in cervix carcinoma. Clinical and Translational Oncology 13:6, 378-384
CrossRef46
Peter G. Rose, Shamshad Ali, Charles W. Whitney, Rachelle Lanciano, Frederick B. Stehman. (2011) Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: A Gynecologic Oncology Group study. Gynecologic Oncology 121:3, 542-545
CrossRef47
S. Marnitz, A. Schneider. (2011) Aktuelle Therapiekonzepte bei Frauen mit Zervixkarzinom. best practice onkologie 6:3, 32-43
CrossRef48
Aditi Bhatt, Shravan Kumar Chinnikatti, B. S. Ajaikumar. (2011) Management of recurrent cancer of the uterine cervix. Oncology Reviews 5:2, 109-117
CrossRef49
Adeline Lim, Serena Sia. (2011) Outcomes of Chemoradiotherapy in Cervical Cancer—The Western Australian Experience. International Journal of Radiation Oncology*Biology*Physics
CrossRef50
Caiping Guo, Kewei Liu, Yi Zheng, Haibo Luo, Hongbo Chen, Laiqiang Huang. (2011) Apoptosis induced by an antagonist peptide against HPV16 E7 in vitro and in vivo via restoration of p53. Apoptosis 16:6, 606-618
CrossRef51
Benjamin T. Gielda, Anand P. Shah, James C. Marsh, Joseph P. Smart, Damian Bernard, Jacob Rotmensch, Katherine L. Griem. (2011) Helical Tomotherapy Delivery of an IMRT Boost in Lieu of Interstitial Brachytherapy in the Setting of Gynecologic Malignancy: Feasibility and Dosimetric Comparison. Medical Dosimetry 36:2, 206-212
CrossRef52
Yi-Ting Huang, Chun-Chieh Wang, Chien-Sheng Tsai, Chyong-Huey Lai, Ting-Chang Chang, Hung-Hsueh Chou, Swei Hsueh, Chien-Kuang Chen, Steve P. Lee, Ji-Hong Hong. (2011) Long-Term Outcome and Prognostic Factors for Adenocarcinoma/Adenosquamous Carcinoma of Cervix After Definitive Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 80:2, 429-436
CrossRef53
Elizabeth L. Jewell, Michael Smrtka, Gloria Broadwater, Fidel Valea, Debra M. Davis, Kimberly C. Nolte, Renea Valea, Evan R. Myers, Gregory Samsa, Laura J. Havrilesky. (2011) Utility Scores and Treatment Preferences for Clinical Early-Stage Cervical Cancer. Value in Health 14:4, 582-586
CrossRef54
G. Giorda, G. Boz, A. Gadducci, E. Lucia, G. De Piero, A. De Paoli, R. Innocente, M. Trovò, R. Sorio, E. Campagnutta. (2011) Multimodality approach in extra cervical locally advanced cervical cancer: Chemoradiation, surgery and intra-operative radiation therapy. A phase II trial. European Journal of Surgical Oncology (EJSO) 37:5, 442-447
CrossRef55
Monica Bacon, Henry Kitchener, Gavin C.E. Stuart, Jan B. Vermorken. (2011) The Global Impact of the Gynecologic Cancer InterGroup in Enhancing Clinical Trials in Ovarian Cancer. International Journal of Gynecological Cancer 21:4, 746-749
CrossRef56
John Farley, Michael W. Sill, Michael Birrer, Joan Walker, Russell J. Schilder, J. Tate Thigpen, Robert L. Coleman, Brigitte E. Miller, Peter G. Rose, Heather A. Lankes. (2011) Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study. Gynecologic Oncology 121:2, 303-308
CrossRef57
Simone Marnitz, Christhardt Köhler, Elena Burova, Waldemar Wlodarczyk, Ulrich Jahn, Arne Grün, Volker Budach, Carmen Stromberger. (2011) Helical Tomotherapy with Simultaneous Integrated Boost After Laparoscopic Staging in Patients with Cervical Cancer: Analysis of Feasibility and Early Toxicity. International Journal of Radiation Oncology*Biology*Physics
CrossRef58
Elly Brockbank, Fani Kokka, Andrew Bryant, Christophe Pomel, Karina Reynolds, Elly Brockbank. 2011. Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. .
CrossRef59
Kate A. McLean, Weiya Zhang, Rebecca F. Dunsmoor-Su, Chirag A. Shah, Heidi J. Gray, Ron E. Swensen, Barbara A. Goff. (2011) Pelvic exenteration in the age of modern chemoradiation. Gynecologic Oncology 121:1, 131-134
CrossRef60
Rebecca McCaffrey, Mert Bahtiyar, Ernest I. Kohorn, Joseph T. Chambers, Peter E. Schwartz, Setsuko K. Chambers. (2011) Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer. International Journal of Gynecological Cancer 21:3, 535-544
CrossRef61
Pierre Lèguevaque, Stéphanie Motton, Martine Delannes, Denis Querleu, Marc Soulé-Tholy, Gerard Tap, Gilles Houvenaeghel. (2011) Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer?. European Journal of Obstetrics & Gynecology and Reproductive Biology 155:2, 188-192
CrossRef62
SungHwan Cho, Senthilkumar Cinghu, Jae-Ran Yu, Woo-Yoon Park. (2011) Helicase-like transcription factor confers radiation resistance in cervical cancer through enhancing the DNA damage repair capacity. Journal of Cancer Research and Clinical Oncology 137:4, 629-637
CrossRef63
Sarah M. McGuire, Yusuf Menda, Laura L. Boles Ponto, Brandie Gross, Malik Juweid, John E. Bayouth. (2011) A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiotherapy and Oncology 99:1, 49-54
CrossRef64
Thea Laurentius, Annelore Altendorf-Hofmann, Oumar Camara, Ingo B. Runnebaum, Thomas G. Wendt. (2011) Impact of age on morbidity and outcome of concurrent radiochemotherapy in high-risk FIGO stage I to IVA carcinoma of the uterine cervix following laparoscopic surgery. Journal of Cancer Research and Clinical Oncology 137:3, 481-488
CrossRef65
Nora T. Kizer, Premal H. Thaker, Feng Gao, Israel Zighelboim, Matthew A. Powell, Janet S. Rader, David G. Mutch, Perry W. Grigsby. (2011) The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer 117:5, 948-956
CrossRef66
Tamer Refaat, Amr Elsaid, Nashaat Lotfy, Krystyna Kiel, William Small, Phillip Nickers, Eric Lartigau. (2011) Concomitant chemoradiotherapy with high dose rate brachytherapy as a definitive treatment modality for locally advanced cervical cancer. Alexandria Journal of Medicine 47:1, 15-24
CrossRef67
Xin Lei, Cheng-Yuan Qian, Yi Qing, Ke-Wei Zhao, Zheng-Zhou Yang, Nan Dai, Zhao-Yang Zhong, Cheng Tang, Zheng Li, Xian-Qing Gu, Qian Zhou, Yan Feng, Yan-Li Xiong, Jin-Lu Shan, Dong Wang. (2011) Californium-252 Brachytherapy Combined with External-Beam Radiotherapy for Cervical Cancer: Long-Term Treatment Results. International Journal of Radiation Oncology*Biology*Physics
CrossRef68
Amnon Amit, Julian Schink, Ari Reiss, Lior Lowenstein. (2011) PET/CT in Gynecologic Cancer: Present Applications and Future Prospects—A Clinician’s Perspective. Obstetrics and Gynecology Clinics of North America 38:1, 1-21
CrossRef69
Amol J. Ghia, Victor J. Gonzalez, Jonathan D. Tward, Antoinette M. Stroup, Lisa Pappas, David K. Gaffney. (2011) Primary Vaginal Cancer and Chemoradiotherapy. International Journal of Gynecological Cancer 21:2, 378-384
CrossRef70
Ann H. Klopp, Patricia J. Eifel. (2011) Chemoradiotherapy for Cervical Cancer in 2010. Current Oncology Reports 13:1, 77-85
CrossRef71
Lisa Capelle, Wendy Stevens, Susan Brooks. (2011) Patterns of care for cervical cancer in Auckland, New Zealand, 2003-2007. Journal of Medical Imaging and Radiation Oncology 55:1, 82-89
CrossRef72
JianHua Gan, Jia Sheng, Zhen Huang. (2011) Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery. Science China Chemistry 54:1, 3-23
CrossRef73
D. Lorusso, S. Mainenti, A. Pietragalla, E. Fusco, P. Malaguti, V. Masciullo, G. Scambia. (2011) Phase II Study on Weekly Bolus Topotecan in Advanced or Recurrent Cervical Cancer. Oncology 80:5-6, 390-394
CrossRef74
Raymond H. Mak, Lia M. Halasz, Cynthia K. Tanaka, Marek Ancukiewicz, Delray J. Schultz, Anthony H. Russell, Akila N. Viswanathan. (2011) Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3–4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecologic Oncology 120:1, 101-107
CrossRef75
Seiji Mabuchi, Tadashi Kimura. (2011) Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer. Chemotherapy Research and Practice 2011, 1-10
CrossRef76
Jung-Joo An, Yoo-Young Lee, Jin Young Park, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae. (2011) Prognostic value of pre-treatment SCC-Ag level in patients with cervical cancer. Korean Journal of Obstetrics & Gynecology 54:8, 428
CrossRef77
John B. Liao, Stephanie Jean, Ivy Wilkinson-Ryan, Ashley E. Ford, Janos L. Tanyi, Andrea R. Hagemann, Lilie L. Lin, Cindy M. McGrath, Stephen C. Rubin. (2011) Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: A clinically recalcitrant entity. Gynecologic Oncology 120:1, 108-112
CrossRef78
Na Wang, Quan-Lin Guan, Kai Wang, Xin Zhou, Chen Gao, Han-Teng Yang, Tian-Gen Ni. (2011) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Archives of Gynecology and Obstetrics 283:1, 103-108
CrossRef79
Susy M. E. Scholl, Gemma Kenter, Christian Kurzeder, Philippe Beuzeboc. (2011) Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective. ISRN Oncology 2011, 1-13
CrossRef80
Charu Sharma, Israel Deutsch, David P. Horowitz, Dawn L. Hershman, Sharyn N. Lewin, Yu-Shiang Lu, Alfred I. Neugut, Thomas J. Herzog, Clifford K. Chao, Jason D. Wright. (2011) Patterns of care and treatment outcomes for elderly women with cervical cancer. Cancern/a-n/a
CrossRef81
Hae Nam Lee, Keun Ho Lee, Dae Woo Lee, Yong Seok Lee, Eun Kyung Park, Jong Sup Park. (2011) Weekly Cisplatin Therapy Compared With Triweekly Combination Chemotherapy as Concurrent Adjuvant Chemoradiation Therapy After Radical Hysterectomy for Cervical Cancer. International Journal of Gynecological Cancer 21:1, 128-136
CrossRef82
Shailesh Puntambekar, Saravana Rajamanickam, Geetanjali Agarwal, Saurabh Joshi, Neeraj Rayate, Avanish Deshmukh. (2011) Laparoscopic Posterior Exenteration in Advanced Gynecologic Malignant Disease. Journal of Minimally Invasive Gynecology 18:1, 59-63
CrossRef83
Tatsuya Nakamura, Nobukazu Fuwa, Kanako Takayama, Haruo Inokuchi, Takuya Tomoda, Akinori Takada, Chiyoko Makita, Miho Shiomi, Jun-ichi Yokouchi, Kazuo Watanabe. (2011) Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer. Head & Neckn/a-n/a
CrossRef84
Shankar Siva, Alan Herschtal, Jessica M. Thomas, David M. Bernshaw, Suki Gill, Rodney J. Hicks, Kailash Narayan. (2011) Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancern/a-n/a
CrossRef85
Albert J. Chang, Susan Richardson, Perry W. Grigsby, Julie K. Schwarz. (2010) Split-Field Helical Tomotherapy With or Without Chemotherapy for Definitive Treatment of Cervical Cancer. International Journal of Radiation OncologyBiologyPhysics
CrossRef86
Leslie M. Randall, Bradley J. Monk, James Moon, Ricardo Parker, Muthana Al-Ghazi, Sharon Wilczynski, John P. Fruehauf, Maurie Markman, Robert A. Burger. (2010) Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group Study. Gynecologic Oncology 119:3, 417-421
CrossRef87
G. Ferrandina, P.A. Margariti, D. Smaniotto, M. Petrillo, M.G. Salerno, A. Fagotti, G. Macchia, A.G. Morganti, N. Cellini, G. Scambia. (2010) Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecologic Oncology 119:3, 404-410
CrossRef88
Hideomi Yamashita, Kae Okuma, Kei Kawana, Shunsuke Nakagawa, Katsutoshi Oda, Tetsu Yano, Shino Kobayashi, Reiko Wakui, Kuni Ohtomo, Keiichi Nakagawa. (2010) Comparison Between Conventional Surgery Plus Postoperative Adjuvant Radiotherapy and Concurrent Chemoradiation for FIGO Stage IIB Cervical Carcinoma. American Journal of Clinical Oncology 33:6, 583-586
CrossRef89
Gabriella Macchia, Gabriella Ferrandina, Francesco Legge, Francesco Deodato, Valeria Ruggieri, Domenica Lorusso, Gilbert D. A. Padula, Vincenzo Valentini, Numa Cellini, Giovanni Scambia, Alessio G. Morganti. (2010) Prolonged Chemoradiation in Locally Advanced Carcinoma of the Uterine Cervix. American Journal of Clinical Oncology 33:6, 577-582
CrossRef90
Cheryl Crozier, Beth Erickson-Wittmann, Benjamin Movsas, Jean Owen, Najma Khalid, J. Frank Wilson. (2010) Shifting the Focus to Practice Quality Improvement in Radiation Oncology. Journal for Healthcare Qualityno-no
CrossRef91
Chel Hun Choi, Yoo-Young Lee, Min Kyu Kim, Tae-Joong Kim, Jeong-Won Lee, Hee Rim Nam, Seung Jae Huh, Je-Ho Lee, Duk-Soo Bae, Byoung-Gie Kim. (2010) A Matched-Case Comparison to Explore the Role of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer. International Journal of Radiation OncologyBiologyPhysics
CrossRef92
Miyako Nakawatari, Mayumi Iwakawa, Tatsuya Ohno, Shingo Kato, Etsuko Nakamura, Yu Ohkubo, Tomoaki Tamaki, Takashi Imai. (2010) Change in fibroblast growth factor 2 expression as an early phase radiotherapy-responsive marker in sequential biopsy samples from patients with cervical cancer during fractionated radiotherapy. Cancer 116:21, 5082-5092
CrossRef93
Teresa L. Rutledge, Seth R. Heckman, Clifford Qualls, Carolyn Y. Muller, Rebecca G. Rogers. (2010) Pelvic floor disorders and sexual function in gynecologic cancer survivors: a cohort study. American Journal of Obstetrics and Gynecology 203:5, 514.e1-514.e7
CrossRef94
Charles A. Kunos, Tomas Radivoyevitch, John Pink, Song-Mao Chiu, Tammy Stefan, James Jacobberger, Timothy J. Kinsella. (2010) Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers. Radiation Research 174:5, 574-581
CrossRef95
J. Alejandro Rauh-Hain, Whitfield B. Growdon, John O. Schorge, A.K. Goodman, David M. Boruta, Christopher McCann, Neil S. Horowitz, Marcela G. del Carmen. (2010) Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecologic Oncology 119:2, 299-304
CrossRef96
Yun Liang, Karen Messer, Brent S. Rose, John H. Lewis, Steve B. Jiang, Catheryn M. Yashar, Arno J. Mundt, Loren K. Mell. (2010) Impact of Bone Marrow Radiation Dose on Acute Hematologic Toxicity in Cervical Cancer: Principal Component Analysis on High Dimensional Data. International Journal of Radiation Oncology*Biology*Physics 78:3, 912-919
CrossRef97
Christine Ellingsen, Tormod A.M. Egeland, Kanthi Galappathi, Einar K. Rofstad. (2010) Dynamic contrast-enhanced magnetic resonance imaging of human cervical carcinoma xenografts: Pharmacokinetic analysis and correlation to tumor histomorphology. Radiotherapy and Oncology 97:2, 217-224
CrossRef98
Mei-Qin Zhang, Su-Ping Liu, Xiang-E. Wang. (2010) Concurrent Chemoradiotherapy With Paclitaxel and Nedaplatin Followed by Consolidation Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix: Preliminary Results of a Phase II Study. International Journal of Radiation Oncology*Biology*Physics 78:3, 821-827
CrossRef99
Elesyia D. Haynes-Outlaw, Perry W. Grigsby. (2010) The Role of FDG-PET/CT in Cervical Cancer: Diagnosis, Staging, Radiation Treatment Planning and Follow-Up. PET Clinics 5:4, 435-446
CrossRef100
Amnon Amit, Julian Schink, Ari Reiss, Lior Lowenstein. (2010) PET/CT in Gynecologic Cancer: Present Applications and Future Prospects—A Clinician’s Perspective. PET Clinics 5:4, 391-405
CrossRef101
Shigeki Takeshita, Tsunekazu Kita, Yoshiyuki Motoike, Koichi Umezawa, Soichi Sugisaki, Sachiyo Matsumoto, Yasuhiro Matsumoto, Eiji Ryo, Takuya Ayabe. (2010) Postoperative concurrent chemoradiotherapy for the high-risk uterine cervical cancer. Journal of Obstetrics and Gynaecology Research 36:5, 1009-1014
CrossRef102
Simone Marnitz, Carmen Stromberger, Michael Kawgan-Kagan, Waldemar Wlodarczyk, Ulrich Jahn, Achim Schneider, Uwe Ulrich, Volker Budach, Christhardt Köhler. (2010) Helical Tomotherapy in Cervical Cancer Patients. Strahlentherapie und Onkologie 186:10, 572-579
CrossRef103
Nicoletta Colombo, Michele Peiretti. (2010) Critical Review of Neoadjuvant Chemotherapy Followed by Surgery for Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer 20, S47-S48
CrossRef104
Mark H Einstein, Rébécca Phaëton. (2010) Issues in cervical cancer incidence and treatment in HIV. Current Opinion in Oncology 22:5, 449-455
CrossRef105
C.L. Vale, J.F. Tierney, S.E. Davidson, K.J. Drinkwater, P. Symonds. (2010) Substantial Improvement in UK Cervical Cancer Survival with Chemoradiotherapy: Results of a Royal College of Radiologists’ Audit. Clinical Oncology 22:7, 590-601
CrossRef106
Zeina Al-Mansour, Claire Verschraegen. (2010) Locally advanced cervical cancer: what is the standard of care?. Current Opinion in Oncology 22:5, 503-512
CrossRef107
Rajiv Samant, Sofya Kobeleva, Choan E, Khalid Balaraj, Tien Le, Michael Fung-Kee-Fung. (2010) Evaluating Contemporary Radiotherapy Approaches in the Primary Treatment of Cervical Cancer. International Journal of Gynecological Cancer 20:6, 1087-1091
CrossRef108
Gabriella Macchia, Gabriella Ferrandina, Francesco Deodato, Valeria Ruggieri, Mariangela Massaccesi, Vanda Salutari, Vincenzo Valentini, Numa Cellini, Giovanni Scambia, Alessio G. Morganti. (2010) Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: Results of a phase I study (LARA-CC-1). Gynecologic Oncology 118:2, 128-133
CrossRef109
Alpana Sharma, Medha Rajappa, Abhigyan Satyam, Manoj Sharma. (2010) Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response. Molecular and Cellular Biochemistry 341:1-2, 65-72
CrossRef110
V. LOIZZI, G. CORMIO, L. SELVAGGI, C. CARRIERO, G. PUTIGNANO. (2010) Locally advanced cervical cancer associated with complete uterine prolapse. European Journal of Cancer Care 19:4, 548-550
CrossRef111
Olivier Poujade, Philippe Morice, Roman Rouzier, Patrick Madelenat, Fabrice Lecuru, Jean-Michel Muray, Patrice Mathevet, Séverine Alran, Remy J. Salmon, Fabien Reyal. (2010) Pathologic Response Rate After Concomitant Neo-Adjuvant Radiotherapy and Chemotherapy for Adenocarcinoma of the Uterine Cervix. International Journal of Gynecological Cancer 20:5, 815-820
CrossRef112
Danny Rischin, Kailash Narayan, Amit M. Oza, Linda Mileshkin, David Bernshaw, Jimin Choi, Rodney Hicks, Bev McClure, Anthony Fyles. (2010) Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:5, 827-833
CrossRef113
Shingo Kato, Tatsuya Ohno, Kullathorn Thephamongkhol, Yaowalak Chansilpa, Yang Yuxing, C.R. Beena Devi, Anita Z. Bustam, Miriam J.C. Calaguas, Rey H. de los Reyes, Chul-Koo Cho, To Anh Dung, Nana Supriana, Hideyuki Mizuno, Takashi Nakano, Hirohiko Tsujii. (2010) Multi-Institutional Phase II Clinical Study of Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer in East and Southeast Asia. International Journal of Radiation Oncology*Biology*Physics 77:3, 751-757
CrossRef114
Elizabeth A. Kidd, Barry A. Siegel, Farrokh Dehdashti, Janet S. Rader, Sasa Mutic, David G. Mutch, Matthew A. Powell, Perry W. Grigsby. (2010) Clinical Outcomes of Definitive Intensity-Modulated Radiation Therapy With Fluorodeoxyglucose–Positron Emission Tomography Simulation in Patients With Locally Advanced Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 77:4, 1085-1091
CrossRef115
Huyen Q. Pham. 2010. Vaginal Carcinoma. , 361-363.
CrossRef116
Ram EITAN, Hanoch LEVAVI, Yoav PELED, Ronen BRENNER, Gad SABAH, Alon BEN-ARIE, Ram DGANI, Ami FISHMAN, Aaron SULKES, Eyal FENIG, Claude KOREN. (2010) Should simple hysterectomy be added after chemo-radiation for stage IB2 and bulky IIA cervical carcinoma?. Australian and New Zealand Journal of Obstetrics and Gynaecology 50:3, 289-293
CrossRef117
Katsunori Kashima, Tetsuro Yahata, Kazuyuki Fujita, Kenichi Tanaka. (2010) Analysis of the complications after radical hysterectomy for stage IB, IIA and IIB uterine cervical cancer patients. Journal of Obstetrics and Gynaecology Research 36:3, 555-559
CrossRef118
Noriyuki Yamauchi, Hiroshi Sameshima, Kazuko Fukushima, Kimihiro Nagai, Tsuyomu Ikenoue. (2010) A Randomized Trial of Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Radiotherapy Alone in Stage IIIb Carcinoma of the Uterine Cervix. Journal of Gynecologic Surgery 26:2, 105-113
CrossRef119
Larry E. Puls, Bunny Phillips, Chris Schammel, James E. Hunter, David Griffin. (2010) A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma. Medical Oncology 27:2, 368-372
CrossRef120
Maaike A. van der Aa, Th. J. M. Helmerhorst, Sabine Siesling, Sietske Riemersma, Jan Willem Coebergh. (2010) Vaginal and (Uncommon) Cervical Cancers in the Netherlands, 1989-2003. International Journal of Gynecological Cancer 20:4, 638-645
CrossRef121
Peter G. Rose, Shamshad Ali, Charles W. Whitney, Rachelle Lanciano, Frederick B. Stehman. (2010) Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: A Gynecologic Oncology Group study. Gynecologic Oncology 117:2, 270-275
CrossRef122
Krishnansu S. Tewari, J. Tate Thigpen. (2010) Debate: Cisplatin Plus Paclitaxel in the Treatment of Patients With Metastatic/Recurrent Cervical Cancer. Clinical Ovarian Cancer 3:1, 14-20
CrossRef123
M. Fabbro, L. Gladieff, F. Guichard, M. El Demery, F. Dalenc, C. Kerr, M. Delannes, D. Paraiso, E. Pujade-Lauraine, J.-E. Kurtz. (2010) Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial. Gynecologic Oncology 117:2, 276-280
CrossRef124
Beth M. Beadle, Anuja Jhingran, Sue S. Yom, Pedro T. Ramirez, Patricia J. Eifel. (2010) Patterns of Regional Recurrence After Definitive Radiotherapy for Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 76:5, 1396-1403
CrossRef125
Duangmani Thanapprapasr, Adisak Nartthanarung, Puchong Likittanasombut, Nathpong Israngura Na Ayudhya, Chuenkamon Charakorn, Umaporn Udomsubpayakul, Thanya Subhadarbandhu, Sarikapan Wilailak. (2010) Bone Metastasis in Cervical Cancer Patients Over a 10-Year Period. International Journal of Gynecological Cancer 20:3, 373-378
CrossRef126
Jonathan Teh, Swee Peng Yap, Ivan Tham, Vijay K. Sethi, Eu Jin Chua, Richard Yeo, Tew Hong Ho, Eng Hseon Tay, Yin Nin Chia, Lay Tin Soh, Hoon Seng Khoo-Tan. (2010) Concurrent Chemoradiotherapy Incorporating High-Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma. International Journal of Gynecological Cancer 20:3, 428-433
CrossRef127
Elizabeth K. Nugent, Ashley S. Case, John T. Hoff, Israel Zighelboim, Lorri L. DeWitt, Kim Trinkhaus, David G. Mutch, Premal H. Thaker, L. Stewart Massad, Janet S. Rader. (2010) Chemoradiation in locally advanced cervical carcinoma: An analysis of cisplatin dosing and other clinical prognostic factors. Gynecologic Oncology 116:3, 438-441
CrossRef128
Bogdan Torbé, Michał Falco, Andrzej Torbé, Przemysław Ciepiela, Rafał Kurzawa. (2010) Radiotherapy versus radiochemotherapy with cisplatin in treatment of cervical cancer. Medical Oncology 27:1, 1-8
CrossRef129
Dennis Yi-Shin Kuo, Stephanie V. Blank, Paul J. Christos, Mimi Kim, Thomas A. Caputo, Bhavana Pothuri, Dawn Hershman, Noah Goldman, Percy S. Ivy, Carolyn D. Runowicz, Franco Muggia, Gary L. Goldberg, Mark H. Einstein. (2010) Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study. Gynecologic Oncology 116:3, 442-446
CrossRef130
E. P. M. Jansen, H. Boot, R. Dubbelman, M. Verheij, A. Cats. (2010) Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Annals of Oncology 21:3, 530-534
CrossRef131
Alfonso Dueñas-González, Lucely Cetina, Jaime Coronel, Déborah Martínez-Baños. (2010) Pharmacotherapy Options for Locally Advanced and Advanced Cervical Cancer. Drugs 70:4, 403-432
CrossRef132
Nathan Bittner, Gregory S. Merrick, Kent E. Wallner, Wayne M. Butler, Robert Galbreath, Edward Adamovich. (2010) Whole-Pelvis Radiotherapy in Combination With Interstitial Brachytherapy: Does Coverage of the Pelvic Lymph Nodes Improve Treatment Outcome in High-Risk Prostate Cancer?. International Journal of Radiation Oncology*Biology*Physics 76:4, 1078-1084
CrossRef133
Kathleen M. Schmeler, Anuja Jhingran, Revathy B. Iyer, Charlotte C. Sun, Patricia J. Eifel, Pamela T. Soliman, Pedro T. Ramirez, Michael Frumovitz, Diane C. Bodurka, Anil K. Sood. (2010) Pelvic fractures after radiotherapy for cervical cancer. Cancer 116:3, 625-630
CrossRef134
Stéphanie Motton, Gilles Houvenaeghel, Martine Delannes, Denis Querleu, Marc Soulé-Tholy, Jean Hoff, Pierre Lèguevaque. (2010) Results of Surgery After Concurrent Chemoradiotherapy in Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:2, 268-275
CrossRef135
Marcel Verheij, Conchita Vens, Baukelien van Triest. (2010) Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective. Drug Resistance Updates 13:1-2, 29-43
CrossRef136
M. Herbolsheimer. (2010) Zu hohe Cisplatin-Dosen bei der simultanen Radiochemotherapie des Zervixkarzinoms?. Der Onkologe 16:2, 187-188
CrossRef137
Jen-Yu Tseng, Ming-Shien Yen, Nae-Fong Twu, Chiung-Ru Lai, Huann-Cheng Horng, Chien-Chih Tseng, Kuan-Chong Chao, Chi-Mou Juang. (2010) Prognostic nomogram for overall survival in stage IIB-IVA cervical cancer patients treated with concurrent chemoradiotherapy. American Journal of Obstetrics and Gynecology 202:2, 174.e1-174.e7
CrossRef138
Martine Franckena, Jacoba van der Zee. (2010) Use of combined radiation and hyperthermia for gynecological cancer. Current Opinion in Obstetrics and Gynecology 22:1, 9-14
CrossRef139
Ruijie Yang, Shouping Xu, Weijuan Jiang, Junjie Wang, Chuanbin Xie. (2010) Dosimetric comparison of postoperative whole pelvic radiotherapy for endometrial cancer using three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy. Acta Oncologica 49:2, 230-236
CrossRef140
Lara Barazzuol, Neil G. Burnet, Raj Jena, Bleddyn Jones, Sarah J. Jefferies, Norman F. Kirkby. (2010) A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. Journal of Theoretical Biology 262:3, 553-565
CrossRef141
Astrid Baalbergen, Yerney Veenstra, Lukas L Stalpers, Anca C Ansink, Astrid Baalbergen. 2010. Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. .
CrossRef142
, Claire L Vale. 2010. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. .
CrossRef143
Rafael Martínez-Monge, Miren Gaztañaga, José Manuel Aramendía, Mauricio Cambeiro, Leire Arbea, Jaime Espinós, José Javier Aristu, Matías Jurado. (2010) A Phase II Trial of Less Than 7 Weeks of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:1, 133-140
CrossRef144
José Pérez-Regadera, Alfonso Sánchez-Muñoz, Javier De-la-Cruz, Claudio Ballestín, David Lora, Rosa García-Martín, Lorenzo Alonso-Carrión, Cesar Mendiola, Eduardo Lanzós. (2010) Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:1, 164-172
CrossRef145
Tae Jin Han, Hong-Gyun Wu, Hak Jae Kim, Sung Whan Ha, Soon-Beom Kang, Yong-Sang Song, Noh-Hyun Park. (2010) Effects of Concurrent Chemotherapy and Postoperative Prophylactic Paraaortic Irradiation for Cervical Cancer with Common Iliac Node Involvement. The Journal of the Korean Society for Therapeutic Radiology and Oncology 28:3, 125
CrossRef146
Dong Hoon Suh, Jae Weon Kim, Mohamad Farid Aziz, Uma K. Devi, Hextan Y. S. Ngan, Joo-Hyun Nam, Seung Cheol Kim, Tomoyasu Kato, Hee Sug Ryu, Shingo Fujii, Yoon Soon Lee, Jong Hyeok Kim, Tae-Joong Kim, Young Tae Kim, Kung-Liahng Wang, Taek Sang Lee, Kimio Ushijima, Sang-Goo Shin, Yin Nin Chia, Sarikapan Wilailak, Sang Yoon Park, Hidetaka Katabuchi, Toshiharu Kamura, Soon-Beom Kang. (2010) Asian society of gynecologic oncology workshop 2010. Journal of Gynecologic Oncology 21:3, 137
CrossRef147
Claudio C. Carmo, Ronir R. Luiz. (2010) Indication of Radiotherapy for Women With Cervical Cancer in Rio De Janeiro, Brazil. International Journal of Gynecological Cancer 20:1, 158-163
CrossRef148
Lilian T. Gien, Marie-Claude Beauchemin, Gillian Thomas. (2010) Adenocarcinoma: A unique cervical cancer. Gynecologic Oncology 116:1, 140-146
CrossRef149
C. C. E. Koning, J. S. A. Belderbos, A. L. J. Uitterhoeve. (2010) From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions. Chemotherapy Research and Practice 2010, 1-5
CrossRef150
Fiona J Gilbert, Trevor S Ahearn. (2009) Dynamic contrast-enhanced MRI in cancer. Imaging in Medicine 1:2, 173-186
CrossRef151
Yong Bae Kim, Ik Jae Lee, Song Yih Kim, Jun Won Kim, Hong In Yoon, Sang Wun Kim, Sunghoon Kim, Young Tae Kim, Chang Ok Suh, Gwi Eon Kim. (2009) Tumor Heterogeneity of FIGO Stage III Carcinoma of the Uterine Cervix. International Journal of Radiation Oncology*Biology*Physics 75:5, 1323-1328
CrossRef152
Seiji Mabuchi, Ken-ichirou Morishige, Fumiaki Isohashi, Yasuo Yoshioka, Takashi Takeda, Toshiya Yamamoto, Kiyoshi Yoshino, Takayuki Enomoto, Takehiro Inoue, Tadashi Kimura. (2009) Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecologic Oncology 115:3, 482-487
CrossRef153
Jamal Rahaman, Norma Steiner, Monica Prasad Hayes, Linus Chuang, David Fishman, Herbert Gretz III. (2009) Chemotherapy for Gynecologic Cancers. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:6, 577-588
CrossRef154
Daniel H. Kim, Alice Wang-Chesebro, Vivian Weinberg, Jean Pouliot, Lee-May Chen, Joycelyn Speight, Ramey Littell, I.-Chow Hsu. (2009) High–Dose Rate Brachytherapy Using Inverse Planning Simulated Annealing for Locoregionally Advanced Cervical Cancer: A Clinical Report With 2-Year Follow-Up. International Journal of Radiation Oncology*Biology*Physics 75:5, 1329-1334
CrossRef155
Maaike A. van der Aa, Sabine Siesling, Lonneke V. v.d. Poll-Franse, Eltjo M. Schutter, Marnix L. Lybeert, Jan Willem W. Coebergh. (2009) Age-specific differences in the treatment of cervical cancer in the east and the south of The Netherlands 1989–2004. European Journal of Obstetrics & Gynecology and Reproductive Biology 147:1, 78-82
CrossRef156
Heitor Ricardo Cosiski Marana, Jurandyr Moreira de Andrade, Francisco José Cândido dos Reis, Daniel Guimarães Tiezzi, Fábio Eduardo Zola, Willan Simões Clagnan, Alexandre Pavan Garieri. (2009) Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy. Journal of Surgical Oncology 100:6, 505-510
CrossRef157
Scott I.K. Semple, Vanessa N. Harry, David E. Parkin, Fiona J. Gilbert. (2009) A Combined Pharmacokinetic and Radiologic Assessment of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Response to Chemoradiation in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 75:2, 611-617
CrossRef158
Yuko Kaneyasu, Nobutaka Nagai, Yasushi Nagata, Yasutoshi Hashimoto, Shintaro Yuki, Yuji Murakami, Masahiro Kenjo, Hideaki Kakizawa, Naoyuki Toyota, Hisaya Fujiwara, Yoshiki Kudo, Katsuhide Ito. (2009) Intra-Arterial Infusion Chemotherapy Using Cisplatin With Radiotherapy for Stage III Squamous Cell Carcinoma of the Cervix. International Journal of Radiation Oncology*Biology*Physics 75:2, 369-377
CrossRef159
Alpana Sharma, Medha Rajappa, Abhigyan Satyam, Manoj Sharma. (2009) Cytokines (TH1 and TH2) in Patients With Advanced Cervical Cancer Undergoing Neoadjuvant Chemoradiation. International Journal of Gynecological Cancer 19:7, 1269-1275
CrossRef160
Shohreh Nafisi, Zeinab Norouzi. (2009) A Comparative Study on the Interaction of Cis - and Trans -Platin with DNA and RNA. DNA and Cell Biology 28:9, 469-477
CrossRef161
P.E. Colombo, M.M. Bertrand, M. Gutowski, A. Mourregot, M. Fabbro, B. Saint-Aubert, F. Quenet, S. Gourgou, C. Kerr, P. Rouanet. (2009) Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: Surgical morbidity and oncological results. Gynecologic Oncology 114:3, 404-409
CrossRef162
Mihály Patyánik, Csaba Nemeskéri, Zsuzsa Póti, Dániel Sinkó, Csilla Pesznyák, Réka Király, Róbert Kois, Árpád Mayer. (2009) Concomitant Radiochemotherapy of Cervical Cancer. Strahlentherapie und Onkologie 185:9, 582-587
CrossRef163
Jennifer M. Tornatta, Janet S. Carpenter, Jeanne Schilder, Higinia R. Cardenes. (2009) Representations of Vaginal Symptoms in Cervical Cancer Survivors. Cancer Nursing 32:5, 378-384
CrossRef164
José Humberto Tavares Guerreiro Fregnani, Maria do Rosário Dias de Oliveira Latorre, Pablo Roberto Novik, Ademar Lopes, Júnea Cáris de Oliveira, Audrey Tieko Tsunoda, Fernando Augusto Soares. (2009) Extent of pelvic lymphadenectomy in women with squamous cell carcinoma of the uterine cervix: Is there any prognostic value?. Journal of Surgical Oncology 100:3, 252-257
CrossRef165
Mylin A. Torres, Anuja Jhingran, Howard D. Thames, Charles F. Levenback, Diane C. Bodurka, Lois M. Ramondetta, Patricia J. Eifel. (2009) Concurrent Chemoradiation in the Routine Management of Patients With Cervical Cancer. International Journal of Gynecological Cancer 19:6, 1107-1112
CrossRef166
E. Prasad, P.N. Viswanathan, V.F. Rangad, S. Pavamani, T.S. Ram. (2009) Maximum Tolerated Dose and Early Response — Results of a Phase I Trial of Paclitaxel and Cisplatin with Radiation Therapy in Carcinoma of the Cervix1. Clinical Oncology 21:6, 488-493
CrossRef167
Vanessa N. Harry, Fiona J. Gilbert, David E. Parkin. (2009) Predicting the Response of Advanced Cervical and Ovarian Tumors to Therapy. Obstetrical & Gynecological Survey 64:8, 548-560
CrossRef168
Sujana Movva, Lorna Rodriguez, Hugo Arias-Pulido, Claire Verschraegen. (2009) Novel chemotherapy approaches for cervical cancer. Cancer 115:14, 3166-3180
CrossRef169
Takahiro Kasamatsu, Takashi Onda, Morio Sawada, Tomoyasu Kato, Shun-ichi Ikeda. (2009) Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation. Gynecologic Oncology 114:1, 69-74
CrossRef170
K. Shibata, H. Kajiyama, E. Yamamoto, M. Terauchi, K. Ino, S. Nomura, A. Nawa, M. Kawai, F. Kikkawa. (2009) Effectiveness of preoperative concurrent chemoradiation therapy (CCRT) for locally advanced adenocarcinoma of cervix. European Journal of Surgical Oncology (EJSO) 35:7, 768-772
CrossRef171
Lyndsay J Willmott, Bradley J Monk. (2009) Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert Review of Anticancer Therapy 9:7, 895-903
CrossRef172
Kari L. Ring, Jennifer L. Young, Neal E. Dunlap, Willie A. Andersen, Bernard F. Schneider. (2009) Extended-field radiation therapy with whole pelvis radiotherapy and cisplatin chemosensitization in the treatment of IB2-IIIB cervical carcinoma: a retrospective review. American Journal of Obstetrics and Gynecology 201:1, 109.e1-109.e6
CrossRef173
William T. C. Yuh, Nina A. Mayr, David Jarjoura, Dee Wu, John C. Grecula, Simon S. Lo, Susan M. Edwards, Vincent A. Magnotta, Steffen Sammet, Hualin Zhang, Joseph F. Montebello, Jeffrey Fowler, Michael V. Knopp, Jian Z. Wang. (2009) Predicting Control of Primary Tumor and Survival by DCE MRI During Early Therapy in Cervical Cancer. Investigative Radiology 44:6, 343-350
CrossRef174
David H. Moore. (2009) Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?. Gynecologic Oncology 113:3, 379-383
CrossRef175
Maurie Markman. (2009) Presentation of Chemotherapy Options for Cervix Cancer on Cancer-Related Internet Sites. Journal of Women's Health 18:6, 827-829
CrossRef176
Pitágoras Baskara Justino, Ronaldo Baroni, Roberto Blasbalg, Heloisa de Andrade Carvalho. (2009) Clinical Tumor Dimensions May Be Useful to Prevent Geographic Miss in Conventional Radiotherapy of Uterine Cervix Cancer—A Magnetic Resonance Imaging–Based Study. International Journal of Radiation Oncology*Biology*Physics 74:2, 503-510
CrossRef177
Yuh-Cheng Yang, K.S. Clifford Chao, Chin-Ping Lin, Yu-Yawn Chen, Kung-Liahng Wang, Yu-Jen Chen. (2009) Oxaliplatin Regulates DNA Repair Responding to Ionizing Radiation and Enhances Radiosensitivity of Human Cervical Cancer Cells. International Journal of Gynecological Cancer 19:4, 782-786
CrossRef178
Edwin A. Alvarez, Aaron H. Wolfson, J. Matt Pearson, Meredith P. Crisp, Luis E. Mendez, Nicholas C. Lambrou, Joseph A. Lucci. (2009) A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer. Gynecologic Oncology 113:2, 195-199
CrossRef179
Bedatri Sinha, Fredrick Stehman, Jeanne Schilder, Lori Clark, Higinia Cardenes. (2009) Indiana University Experience in the Management of Vaginal Cancer. International Journal of Gynecological Cancer 19:4, 686-693
CrossRef180
Jeong-Im Sin, Jung-Min Kim, Sung Hwa Bae, In Hee Lee, Jong Sup Park, Hun Mo Ryoo. (2009) Adoptive Transfer of Human Papillomavirus E7-specific CTL Enhances Tumor Chemoresponse Through the Perforin/Granzyme-mediated Pathway. Molecular Therapy 17:5, 906-913
CrossRef181
Kate Parker, Eve Gallop-Evans, Louise Hanna, Malcolm Adams. (2009) Five Years' Experience Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiotherapy and High-Dose-Rate Brachytherapy: Results From a Single Institution. International Journal of Radiation Oncology*Biology*Physics 74:1, 140-146
CrossRef182
Yoshiyuki Suzuki, Kuniyuki Oka, Tatsuya Ohno, Shingo Kato, Hirohiko Tsujii, Takashi Nakano. (2009) Prognostic impact of mitotic index of proliferating cell populations in cervical cancer patients treated with carbon ion beam. Cancer 115:9, 1875-1882
CrossRef183
Geraldine Jacobson, John Lammli, Gideon Zamba, Lei Hua, Michael J. Goodheart. (2009) Thromboembolic events in patients with cervical carcinoma: Incidence and effect on survival. Gynecologic Oncology 113:2, 240-244
CrossRef184
Elfriede R. Greimel, Raimund Winter, Karin S. Kapp, Josef Haas. (2009) Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psycho-Oncology 18:5, 476-482
CrossRef185
Kenji Umayahara, Nobuhiro Takeshima, Takayuki Nose, Kiyoshi Fujiwara, Yuko Sugiyama, Kuniko Utsugi, Takashi Yamashita, Ken Takizawa. (2009) Phase I Study of Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel Chemotherapy for Locally Advanced Cervical Carcinoma in Japanese Women. International Journal of Gynecological Cancer 19:4, 723-727
CrossRef186
Rosa De Vincenzo, Giulia Amadio, Caterina Ricci, Angelo Licameli, Gabriella Ferrandina, Giovanni Capelli, Giovanni Scambia. (2009) Treatment of cervical cancer in Italy: Strategies and their impact on the women. Vaccine 27, A39-A45
CrossRef187
Fumiaki Isohashi, Yasuo Yoshioka, Masahiko Koizumi, Koji Konishi, Iori Sumida, Yutaka Takahashi, Toshiyuki Ogata, Ken-ichirou Morishige, Takayuki Enomoto, Yoshifumi Kawaguchi, Tadayuki Kotsuma, Kana Adachi, Shoichi Fukuda, Yuichi Akino, Takehiro Inoue. (2009) High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma. Brachytherapy 8:2, 234-239
CrossRef188
Lisa Barbera, Gillian Thomas. (2009) Management of Early and Locally Advanced Cervical Cancer. Seminars in Oncology 36:2, 155-169
CrossRef189
Jaggi Vinita Kumar, D. C. Doval, Ranga Rao, Sudhir Rawal. (2009) A Retrospective Study of Patients With Locally Advanced Cancer of the Cervix Treated With Neoadjuvant Chemotherapy Followed by Radical Surgery. International Journal of Gynecological Cancer 19:3, 417-422
CrossRef190
George A. Plataniotis, Roger G. Dale. (2009) Use of the Concept of Equivalent Biologically Effective Dose (BED) to Quantify the Contribution of Hyperthermia to Local Tumor Control in Radiohyperthermia Cervical Cancer Trials, and Comparison With Radiochemotherapy Results. International Journal of Radiation Oncology*Biology*Physics 73:5, 1538-1544
CrossRef191
R Tozzi, F Lavra, T Cassese, R Garruto Campanile, V Pedicini, M Bignardi, M Scorsetti, A Bertuzzi. (2009) Laparoscopic debulking of bulky lymph nodes in women with cervical cancer: indication and surgical outcomes. BJOG: An International Journal of Obstetrics & Gynaecology 116:5, 688-692
CrossRef192
David Katz, Emma Ito, Fei-Fei Liu. (2009) On the Path to Seeking Novel Radiosensitizers. International Journal of Radiation Oncology*Biology*Physics 73:4, 988-996
CrossRef193
Viorica Nagy, Ovidiu Coza, Claudia Ordeanu, Alexandru Třailă, Alin Rancea, Nicolae Todor, Nicolae Ghilezan. (2009) Radiotherapy versus Concurrent 5-Day Cisplatin and Radiotherapy in Locally Advanced Cervical Carcinoma. Strahlentherapie und Onkologie 185:3, 177-183
CrossRef194
Hwan Mook Kim, Jaeseung Lim, Jong Soon Kang, Song-Kyu Park, Kiho Lee, Jee Youn Kim, Yeon Jin Kim, Jin Tae Hong, Youngsoo Kim, Sang-Bae Han. (2009) Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model. International Immunopharmacology 9:3, 375-380
CrossRef195
Yoshito Terai, Masanori Kanemura, Hiroshi Sasaki, Satoshi Tsunetoh, Yoshimichi Tanaka, Yoshiki Yamashita, Kazuhiro Yamamoto, Isamu Narabayashi, Masahide Ohmichi. (2009) Long-term follow-up of neoadjuvant intraarterial chemotherapy using an original four-lumen double-balloon (4L-DB) catheter for locally advanced uterine cervical cancer. International Journal of Clinical Oncology 14:1, 56-62
CrossRef196
Takafumi Toita. (2009) Current status and perspectives of brachytherapy for cervical cancer. International Journal of Clinical Oncology 14:1, 25-30
CrossRef197
Arthi Vijayaraghavan, Molly Efrusy, Gerhard Lindeque, Greta Dreyer, Christopher Santas. (2009) Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecologic Oncology 112:2, 377-383
CrossRef198
S. Spensley, R.D. Hunter, J.E. Livsey, R. Swindell, S.E. Davidson. (2009) Clinical Outcome for Chemoradiotherapy in Carcinoma of the Cervix. Clinical Oncology 21:1, 49-55
CrossRef199
Vicente Tormo Ferrero, Francisco J. Andreu Martínez, Rafael Cardenal Maciá. (2009) Evaluation of toxicity of surgery and/or chemoirradiation treatment of uterine cervix cancer. Clinical and Translational Oncology 11:2, 109-113
CrossRef200
J. Dimopoulos, R. Pötter. (2009) Postoperative adjuvante Strahlentherapie der Vulva und Vagina. Der Onkologe 15:1, 69-75
CrossRef201
Woo-Young Kim, Suk-Joon Chang, Ki-Hong Chang, Seung-Chul Yoo, Mison Chun, Hee-Sug Ryu. (2009) Differing prognosis of cervical cancer patients with high risk of treatment failure after radical hysterectomy warrants trial treatment modification. Journal of Gynecologic Oncology 20:1, 17
CrossRef202
Min Kyu Kang, Won Park, Yoon-La Choi, Eun Yoon Cho, Geunghwan Ahn, HeeRim Nam, Seung Jae Huh, Yong Chan Ahn, Do Hoon Lim, Dong Ryul Oh, Duk Soo Bae, Byoung Gie Kim. (2009) The Effect of Cyclooxygenase-2 Expression on Tumor Volume Response in Patients Treated with Radiotherapy for Uterine Cervical Cancer. Journal of Korean Medical Science 24:6, 1170
CrossRef203
Takeshi Kodaira, Nobukazu Fuwa, Toru Nakanishi, Hiroyuki Tachibana, Tatsuya Nakamura, Natsuo Tomita, Rie Nakahara, Haruo Inokuchi. (2009) Prospective Study of Alternating Chemoradiotherapy Consisting of Extended-Field Dynamic Conformational Radiotherapy and Systemic Chemotherapy Using 5-FU and Nedaplatin for Patients in High-Risk Group With Cervical Carcinoma. International Journal of Radiation Oncology*Biology*Physics 73:1, 251-258
CrossRef204
Hee Seung Kim, Noh Hyun Park, Hong Gyun Wu, Jeong Yeon Cho, Hyun Hoon Chung, Jae Weon Kim, Yong Sang Song, Seung Hyup Kim, Soon Beom Kang. (2009) Matched-Case Comparison for the Role of Surgery in FIGO Stage Ib1–IIa Squamous Cell Carcinoma of Cervix and Suspicious Para-Aortic Lymph Node Metastasis. Annals of Surgical Oncology 16:1, 133-139
CrossRef205
Yong Wook Jung, San Hui Lee, Ji Heum Paek, Eun Ji Nam, Sang Wun Kim, Jae Hoon Kim, Jae Wook Kim, Young Tae Kim. (2009) Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer. Journal of Gynecologic Oncology 20:3, 151
CrossRef206
J. Dimopoulos, E. Fidarova, R. Pötter. (2009) Definitive Radiotherapie und Radiochemotherapie der Vulva und Vagina. Der Onkologe 15:1, 54-63
CrossRef207
Kidong Kim, Sang-Young Ryu. (2009) Major clinical research advances in gynecologic cancer 2009. Journal of Gynecologic Oncology 20:4, 203
CrossRef208
Eui-Sok Sol, Tae Sung Lee, Suk Bong Koh, Hun Kyu Oh, Gi Won Ye, Youn Seok Choi. (2009) Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel in patients with locally advanced cervical carcinoma. Journal of Gynecologic Oncology 20:1, 28
CrossRef209
David K. Gaffney, Andreas Du Bois, Kailash Narayan, Nick Reed, Takafumi Toita, Sandro Pignata, Peter Blake, Lorraine Portelance, Azmat Sadoyze, Richard Potter, Alessandro Colombo, Marcus Randall, Mansoor R. Mirza, Edward L. Trimble. (2009) Patterns of Care for Radiotherapy in Vulvar Cancer. International Journal of Gynecological Cancer 19:1, 163-167
CrossRef210
Jae Myoung Noh, Won Park, Seung Jae Huh, Eun Yoon Cho, Yoon-La Choi, Je Ho Lee, Duk Soo Bae. (2009) Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma. Journal of Gynecologic Oncology 20:4, 215
CrossRef211
S. Goonatillake, R. Khong, P. Hoskin. (2009) Chemoradiation in Gynaecological Cancer. Clinical Oncology 21:7, 566
CrossRef212
Jeong-Im Sin. (2009) Promises and challenges of human papillomavirus vaccines for cervical cancer. Expert Review of Anticancer Therapy 9:1, 1-5
CrossRef213
Stephanie Servagi-Vernat, Mathieu Bosset, Gilles Crehange, Jöelle Buffet-Miny, Marc Puyraveau, Philippe Maingon, Mariette Mercier, Jean François Bosset. (2009) Feasibility of Chemoradiotherapy for Oesophageal Cancer in Elderly Patients Aged ≥75 Years. Drugs & Aging 26:3, 255-262
CrossRef214
S van Dyk, D Byram, D Bernshaw. (2008) Brachytherapy for cancer of the cervix: An Australian and New Zealand survey of current treatment techniques. Journal of Medical Imaging and Radiation Oncology 52:6, 588-597
CrossRef215
George A. Plataniotis, Roger G. Dale. (2008) Use of Concept of Chemotherapy-Equivalent Biologically Effective Dose to Provide Quantitative Evaluation of Contribution of Chemotherapy to Local Tumor Control in Chemoradiotherapy Cervical Cancer Trials. International Journal of Radiation Oncology*Biology*Physics 72:5, 1538-1543
CrossRef216
J. KODAMA, M. TAKEMOTO, N. SEKI, K. NAKAMURA, A. HONGO, S. MORIYA, S. KANAZAWA, Y. HIRAMATSU. (2008) Phase I study of chemoradiation with nedaplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. International Journal of Gynecological Cancer 18:6, 1300-1304
CrossRef217
Claudio C. Carmo, Ronir R. Luiz, Gustavo Silva. (2008) The effect of addition of chemotherapy to radiotherapy in the treatment of women with cervical cancer: A survival analysis using propensity score. Gynecologic Oncology 111:2, 271-275
CrossRef218
Primoz Petric, Johannes Dimopoulos, Christian Kirisits, Daniel Berger, Robert Hudej, Richard Pötter. (2008) Inter- and intraobserver variation in HR-CTV contouring: Intercomparison of transverse and paratransverse image orientation in 3D-MRI assisted cervix cancer brachytherapy. Radiotherapy and Oncology 89:2, 164-171
CrossRef219
Ji-An Liang, Shang-Wen Chen, Wei-Chun Chang, Yao-Ching Hung, Lian-Shung Yeh, Shih-Neng Yang, Fang-Jen Lin. (2008) Risk Stratification for Failure in Patients with Advanced Cervical Cancer after Concurrent Chemoradiotherapy: Another Way to Optimise Treatment Results. Clinical Oncology 20:9, 683-690
CrossRef220
J. PETSUKSIRI, Y. CHANSILPA, S. THERASAKVICHYA, N. SUNTORNPONG, K. THEPHAMONGKHOL, P. DANKULCHAI, P. MAHASITTHIWAT, N. IEUMWANANONTHACHAI, V. VEERASARN, S. SANGRUCHI, P. PATTARANUTAPORN. (2008) Treatment options in bulky stage IB cervical carcinoma. International Journal of Gynecological Cancer 18:6, 1153-1162
CrossRef221
T Ota, N Takeshima, T Tabata, K Hasumi, K Takizawa. (2008) Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy. British Journal of Cancer 99:8, 1216-1220
CrossRef222
George A. Omura. (2008) Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience. Seminars in Oncology 35:5, 507-521
CrossRef223
J. KODAMA, M. TAKEMOTO, N. SEKI, K. NAKAMURA, A. HONGO, S. KANAZAWA, Y. HIRAMATSU. (2008) Phase I study of weekly nedaplatin and concurrent pelvic radiotherapy as adjuvant therapy after radical surgery for cervical cancer. International Journal of Gynecological Cancer 18:5, 1037-1041
CrossRef224
M. CAIRNS, V. HARRY, T.K. SARKAR, D.E. PARKIN. (2008) Treatment of advanced cervical cancer: a population-based study. European Journal of Cancer Care
CrossRef225
M. GUIOU, W.H. HALL, T. KONIA, S. SCUDDER, G. LEISEROWITZ, J.K. RYU. (2008) Primary clear cell adenocarcinoma of the rectovaginal septum treated with concurrent chemoradiation therapy: a case report. International Journal of Gynecological Cancer 18:5, 1118-1121
CrossRef226
Lucía González-Cortijo, N. Carballo, A. González-Martín, V. Corraliza, L. Chiva de Agustín, F. Lapuente Sastre, J.F. García García, A. Rojo Sebastián, J. Hornedo, R. Colomer. (2008) Novel chemotherapy approaches in chemoradiation protocols. Gynecologic Oncology 110:3, S45-S48
CrossRef227
Oliver Zivanovic, Dennis S Chi. (2008) Surgical resection and reconstruction for advanced and recurrent gynecologic malignancies. Expert Review of Obstetrics & Gynecology 3:5, 677-690
CrossRef228
Edward L. Trimble, Linda C. Harlan, David Gius, Jennifer Stevens, Stephen M. Schwartz. (2008) Patterns of care for women with cervical cancer in the United States. Cancer 113:4, 743-749
CrossRef229
Tsuguhisa Nashiro, Chiaki Yagi, Makoto Hirakawa, Morihiko Inamine, Yutaka Nagai, Kaoru Sakumoto, Wakana Tamaki, Kazuhiko Ogawa, Takafumi Toita, Yoichi Aoki. (2008) Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. International Journal of Clinical Oncology 13:4, 335-339
CrossRef230
J.F. Tierney, C. Vale, P. Symonds. (2008) Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer. Clinical Oncology 20:6, 401-416
CrossRef231
Loren K. Mell, Hanifi Tiryaki, Kang-Hyun Ahn, Arno J. Mundt, John C. Roeske, Bulent Aydogan. (2008) Dosimetric Comparison of Bone Marrow-Sparing Intensity-Modulated Radiotherapy Versus Conventional Techniques for Treatment of Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 71:5, 1504-1510
CrossRef232
Michael A. Bidus, Angela S. Caffrey, Whitney B. You, Charles A. Amezcua, Mildred R. Chernofsky, Ross Barner, Jeffrey Seidman, G. Scott Rose. (2008) Cervical biopsy and excision procedure specimens lack sufficient predictive value for lymph-vascular space invasion seen at hysterectomy for cervical cancer. American Journal of Obstetrics and Gynecology 199:2, 151.e1-151.e4
CrossRef233
Hun-Jung Kim, Woo-Chul Kim. (2008) Pretreatment tumor diameter/volume and pelvic lymph node status assessed by magnetic resonance imaging for uterine cervical carcinoma treated with concurrent chemotherapy and radiotherapy. Journal of Obstetrics and Gynaecology Research 34:4, 529-537
CrossRef234
Markus Vogt, Christhardt Köhler, Simone Marnitz, Chie Hee Cho, Malgorzata Lanowska, Achim Schneider, Volker Budach. (2008) Vaginal herniation after secondary laparoscopic assisted vaginal hysterectomy following primary radiochemotherapy for stage IIIA cervical cancer. Radiotherapy and Oncology 88:2, 285-286
CrossRef235
K.Y. LOOK, J.A. BLESSING, C.M. MICHENER, S.C. RUBIN, P.T. RAMIREZ. (2008) Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International Journal of Gynecological Cancer 18:4, 773-778
CrossRef236
Mark I. Hunter, Krishnansu Tewari, Bradley J. Monk. (2008) Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. American Journal of Obstetrics and Gynecology 199:1, 10-18
CrossRef237
Magnus Jensen, Willy Nerdal. (2008) Anticancer cisplatin interactions with bilayers of total lipid extract from pig brain: A 13C, 31P and 15N solid-state NMR study. European Journal of Pharmaceutical Sciences 34:2-3, 140-148
CrossRef238
C.J. DARUS, M.B. CALLAHAN, Q.-N. NGUYEN, L.M. PASTORE, B.F. SCHNEIDER, L.W. RICE, A.A. JAZAERI. (2008) Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. International Journal of Gynecological Cancer 18:4, 730-735
CrossRef239
Eric Leblanc, Michael Frumovitz, Denis Querleu. (2008) Reply to Lavoué et al.. Gynecologic Oncology 109:3, 428-429
CrossRef240
Numa Cellini, Daniela Smaniotto, Giovanni Scambia, Stefano Luzi, Mario Balducci, Gabriella Ferrandina, Barbara Corvari, Pasquale A. Margariti, Vincenzo Valentini, Giuseppe DʼAgostino. (2008) Chemoradiation With Concomitant Boost Followed by Radical Surgery in Locally Advanced Cervical Cancer: A Dose-Escalation Study. American Journal of Clinical Oncology 31:3, 280-284
CrossRef241
Kiyosumi Shibata, Hiroaki Kajiyama, Mikio Terauchi, Eiko Yamamoto, Kazuhiko Ino, Akihiro Nawa, Fumitaka Kikkawa. (2008) Feasibility and effectiveness of postoperative adjuvant concurrent chemoradiation therapy in Japanese patients with high-risk early-stage cancer of the uterine cervix. International Journal of Clinical Oncology 13:3, 233-238
CrossRef242
X. Carcopino, G. Houvenaeghel, M. Buttarelli, B. Esterni, A. Tallet, A. Goncalves, J. Jacquemier. (2008) Equivalent survival in patients with advanced stage IB–II and III–IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy. European Journal of Surgical Oncology (EJSO) 34:5, 569-575
CrossRef243
Chel Hun Choi, Heeseok Kang, Woo Young Kim, Tae-Joong Kim, Jeong-Won Lee, Seung Jae Huh, Je-Ho Lee, Byoung-Gie Kim, Duk-Soo Bae. (2008) Prognostic Value of Baseline Lymphocyte Count in Cervical Carcinoma Treated With Concurrent Chemoradiation. International Journal of Radiation Oncology*Biology*Physics 71:1, 199-204
CrossRef244
Michael A. Gold, Chunqiao Tian, Charles W. Whitney, Peter G. Rose, Rachelle Lanciano. (2008) Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma. Cancer 112:9, 1954-1963
CrossRef245
K.K.L. CHAN, P. IP, P. KWONG, K.F. TAM, H.Y.S. NGAN. (2008) A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix. International Journal of Gynecological Cancer 18:3, 559-563
CrossRef246
Tatsuya Ohno, Takashi Nakano, Shingo Kato, Cho Chul Koo, Yaowalak Chansilpa, Pittayapoom Pattaranutaporn, Miriam Joy C. Calaguas, Rey H. de los Reyes, Beibei Zhou, Juying Zhou, Raden Susworo, Nana Supriana, To Anh Dung, Fuad Ismail, Sinichiro Sato, Hisao Suto, Yuzuru Kutsutani-Nakamura, Hirohiko Tsujii. (2008) Accelerated Hyperfractionated Radiotherapy for Cervical Cancer: Multi-Institutional Prospective Study of Forum for Nuclear Cooperation in Asia Among Eight Asian Countries. International Journal of Radiation Oncology*Biology*Physics 70:5, 1522-1529
CrossRef247
Bradford P. Whitcomb. (2008) Gynecologic Malignancies. Surgical Clinics of North America 88:2, 301-317
CrossRef248
Andrea K. Ng, Lois B. Travis. (2008) Second Primary Cancers: An Overview. Hematology/Oncology Clinics of North America 22:2, 271-289
CrossRef249
Takafumi Toita, Takeshi Kodaira, Atsunori Shinoda, Takashi Uno, Yuichi Akino, Michihide Mitsumori, Teruki Teshima. (2008) Patterns of Radiotherapy Practice for Patients With Cervical Cancer (1999–2001): Patterns of Care Study in Japan. International Journal of Radiation Oncology*Biology*Physics 70:3, 788-794
CrossRef250
James E. Kendrick, J. Michael Straughn, Patsy G. Oliver, Wenquan Wang, Li Nan, William E. Grizzle, Cecil R. Stockard, Ronald D. Alvarez, Donald J. Buchsbaum. (2008) Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecologic Oncology 108:3, 591-597
CrossRef251
Kathleen N. Moore, Michael A. Gold, D. Scott McMeekin, Joan L. Walker, Teresa Rutledge, Kristin K. Zorn. (2008) Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: Technique and peri-operative outcomes. Gynecologic Oncology 108:3, 466-471
CrossRef252
Tzu-Chen Yen, Lai-Chu See, Chyong-Huey Lai, Chien-Sheng Tsai, Angel Chao, Swei Hsueh, Ji-Hong Hong, Ting-Chang Chang, Koon-Kwan Ng. (2008) Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging 35:3, 493-501
CrossRef253
Martine Franckena, Lukas J.A. Stalpers, Peter C.M. Koper, Ruud G.J. Wiggenraad, Wim J. Hoogenraad, Jan D.P. van Dijk, Carla C. Wárlám-Rodenhuis, Jan J. Jobsen, Gerard C. van Rhoon, Jacoba van der Zee. (2008) Long-Term Improvement in Treatment Outcome After Radiotherapy and Hyperthermia in Locoregionally Advanced Cervix Cancer: An Update of the Dutch Deep Hyperthermia Trial. International Journal of Radiation Oncology*Biology*Physics 70:4, 1176-1182
CrossRef254
T. UNO, A. MITSUHASHI, K. ISOBE, S. YAMAMOTO, H. KAWAKAMI, N. UENO, H. USUI, S. TATE, T. KAWATA, H. ITO. (2008) Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix. International Journal of Gynecological Cancer 18:1, 80-84
CrossRef255
Lisa Barbera, Gillian Thomas. (2008) Venous thromboembolism in cervical cancer. The Lancet Oncology 9:1, 54-60
CrossRef256
Young Seok Kim, Seong Soo Shin, Joo-Hyun Nam, Young-Tak Kim, Yong-Man Kim, Jong Hoon Kim, Eun Kyung Choi. (2008) Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecologic Oncology 108:1, 195-200
CrossRef257
Young Seok Seo, Chul Koo Cho, Seong Yul Yoo, Mi Sook Kim, Kang Mo Yang, Hyung Jun Yoo, Chul Won Choi, Kyung Hee Lee, Eui Don Lee, Sang Young Rhu, Suck Chul Choi, Moon Hong Kim, Beob Jong Kim. (2008) Accelerated Hyperfractionated Radiotherapy for Locally Advanced Uterine Cervix Cancers. The Journal of the Korean Society for Therapeutic Radiology and Oncology 26:1, 24
CrossRef258
Il Jung Choi, Moon Seok Cha, Eunku Seul Park, Myung Seok Han, Youngmin Choi, Goo Hwa Je, Hyun Ho Kim. (2008) The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. Journal of Gynecologic Oncology 19:2, 129
CrossRef259
Gabriella Ferrandina, Francesco Fanfani, Manuela Ludovisi, Anna Fagotti, Arnaldo Carbone, Gianfranco Zannoni, Massimiliano Guerriero, Marco Petrillo, Giovanni Scambia. (2008) Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?. Gynecologic Oncology 108:1, 220-225
CrossRef260
A. Goncalves, M. Fabbro, C. Lhommé, L. Gladieff, J.-M. Extra, A. Floquet, L. Chaigneau, A. Tisseron Carrasco, P. Viens. (2008) A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic Oncology 108:1, 42-46
CrossRef261
T. MORI, K. HOSOKAWA, Y. KINOSHITA, A. WATANABE, H. HONJO. (2008) Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma. International Journal of Gynecological Cancer 18:1, 85-89
CrossRef262
Charles Kunos, Heidi Gibbons, Fiona Simpkins, Steven Waggoner. (2008) Chemotherapy Administration during Pelvic Radiation for Cervical Cancer Patients Aged ≥ 55 Years in the SEER-Medicare Population. Journal of Oncology 2008, 1-7
CrossRef263
M. GOODHEART, G. JACOBSON, B.J. SMITH, L. ZHOU. (2008) Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity. International Journal of Gynecological Cancer 18:1, 95-103
CrossRef264
Makoto Hirakawa, Yutaka Nagai, Morihiko Inamine, Kazuya Kamiyama, Kazuhiko Ogawa, Takafumi Toita, Sadayuki Murayama, Yoichi Aoki. (2008) Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecologic Oncology 108:1, 126-129
CrossRef265
Mylin A. Torres, Anuja Jhingran, Howard D. Thames, Charles F. Levenback, Diane C. Bodurka, Lois M. Ramondetta, Patricia J. Eifel. (2008) Comparison of Treatment Tolerance and Outcomes in Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy in a Prospective Randomized Trial or With Standard Treatment. International Journal of Radiation Oncology*Biology*Physics 70:1, 118-125
CrossRef266
Aaron H. Wolfson, Kathryn Winter, William Crook, Awtar Krishan, Perry W. Grigsby, Arnold M. Markoe, Mitchell Morris, David K. Gaffney, Patricia J. Eifel, Joseph A. Lucci. (2008) Are Increased Tumor Aneuploidy and Heightened Cell Proliferation Along With Heterogeneity Associated With Patient Outcome for Carcinomas of the Uterine Cervix? A Combined Analysis of Subjects Treated in RTOG 9001 and a Single-Institution Trial. International Journal of Radiation Oncology*Biology*Physics 70:1, 111-117
CrossRef267
Y. Yildirim, S. Sehirali, M.E. Avci, C. Yılmaz, K. Ertopcu, S. Tinar, Y. Duman, S. Sayhan. (2008) Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. Gynecologic Oncology 108:1, 154-159
CrossRef268
Isam Lataifeh, Zouhair Amarin, Imad Jaradat. (2007) Stage IIB carcinoma of the cervix that is associated with pelvic kidney: A therapeutic dilemma. American Journal of Obstetrics and Gynecology 197:6, e8-e10
CrossRef269
Elizabeth L. Jewell, Shalini Kulasingam, Evan R. Myers, Angeles Alvarez Secord, Laura J. Havrilesky. (2007) Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: A cost effectiveness analysis. Gynecologic Oncology 107:3, 532-540
CrossRef270
Thumwadee Tangsiriwatthana, Bandit Chumworathayi, Pissamai Yuenyao, Sanguanchoke Luanratanakorn, Jeerichuda Pattamadilok. (2007) Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer. Radiation Medicine 25:10, 502-510
CrossRef271
Edwin P.M. Jansen, Henk Boot, Mark P. Saunders, Tom D.L. Crosby, Ria Dubbelman, Harry Bartelink, Marcel Verheij, Annemieke Cats. (2007) A Phase I–II Study of Postoperative Capecitabine-Based Chemoradiotherapy in Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 69:5, 1424-1428
CrossRef272
Renaud de Crevoisier, Nicholas Sanfilippo, Alain Gerbaulet, Philippe Morice, Christophe Pomel, Damiene Castaigne, Patricia Pautier, Catherine Lhomme, Pierre Duvillard, Christine Haie-meder. (2007) Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiotherapy and Oncology 85:3, 362-370
CrossRef273
Bandit Chumworathayi, Pissamai Yuenyao, Vorachai Tangvorapongchai, Sanguanchoke Luanratanakorn, Jeerichuda Pattamadilok, Srichai Krusun. (2007) Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the first seven cases in Thai women. Radiation Medicine 25:9, 474-479
CrossRef274
S. ACKERMANN, M. W. BECKMANN, F. THIEL, T. BOGENRIEDER. (2007) Topotecan in cervical cancer. International Journal of Gynecological Cancer 17:6, 1215-1223
CrossRef275
Peter G. Rose. (2007) The flower looks as good as its bud. American Journal of Obstetrics and Gynecology 197:5, 443-444
CrossRef276
Frederick B. Stehman, Shamshad Ali, Henry M. Keys, Laila I. Muderspach, Weldon E. Chafe, Donald G. Gallup, Joan L. Walker, Deborah Gersell. (2007) Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. American Journal of Obstetrics and Gynecology 197:5, 503.e1-503.e6
CrossRef277
T Ota, N Takeshima, T Tabata, K Hasumi, K Takizawa. (2007) Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers. British Journal of Cancer 97:8, 1058-1062
CrossRef278
Michelle L. Harrison, Thomas Ind, Peter Blake, Martin E. Gore. 2007. Multidisciplinary Team Management of Gynaecological Cancers. .
CrossRef279
G. Ferrandina, F. Legge, A. Fagotti, F. Fanfani, M. Distefano, A. Morganti, N. Cellini, G. Scambia. (2007) Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: Safety, outcome, and prognostic measures. Gynecologic Oncology 107:1, S127-S132
CrossRef280
Kung-Liahng Wang, Yuh-Cheng Yang, K. S. Clifford Chao, Meng-Hao Wu, Hung-Chi Tai, Tze-Chien Chen, Ming-Chao Huang, Jen-Ruei Chen, Tsung-Hsien Su, Yu-Jen Chen. (2007) Correlation of Traditional Point a With Anatomic Location of Uterine Artery and Ureter in Cancer of the Uterine Cervix. International Journal of Radiation Oncology*Biology*Physics 69:2, 498-503
CrossRef281
Isabelle Cadron, Toon Van Gorp, Frederic Amant, Karin Leunen, Patrick Neven, Ignace Vergote. (2007) Chemotherapy for recurrent cervical cancer. Gynecologic Oncology 107:1, S113-S118
CrossRef282
E P M Jansen, H Boot, R Dubbelman, H Bartelink, A Cats, M Verheij. (2007) Postoperative chemoradiotherapy in gastric cancer – a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. British Journal of Cancer 97:6, 712-716
CrossRef283
Vincent Lavoué, Anne-Sophie Bats, Roman Rouzier, Charles Coutant, Emmanuel Barranger, Emile Daraï. (2007) Sentinel lymph node procedure followed by laparoscopic pelvic and paraaortic lymphadenectomy in women with IB2-II cervical cancer. Annals of Surgical Oncology 14:9, 2654-2661
CrossRef284
Pierluigi Benedetti Panici, Filippo Bellati, Natalina Manci, Milena Pernice, Francesco Plotti, Violante Di Donato, Marco Calcagno, Marzio Angelo Zullo, Ludovico Muzii, Roberto Angioli. (2007) Neoadjuvant Chemotherapy Followed by Radical Surgery in Patients Affected by FIGO Stage IVA Cervical Cancer. Annals of Surgical Oncology 14:9, 2643-2648
CrossRef285
Takashi Nakano, Shingo Kato, Jianping Cao, Juying Zhou, Raden Susworo, Nana Supriana, Shinichiro Sato, Tatsuya Ohno, Hisao Suto, Yuzuru Nakamura, Chul-Koo Cho, Fuad B. Ismail, Miriam J.C. Calaguas, Rey H. de los Reyes, Yaowalak Chansilpa, Kullathom Thephamongkhol, Nguyen Ba Duc, To Anh Dung, Hirohiko Tsujii. (2007) A regional cooperative clinical study of radiotherapy for cervical cancer in east and south-east Asian countries. Radiotherapy and Oncology 84:3, 314-319
CrossRef286
Kathleen N. Moore, Michael A. Gold, D. Scott McMeekin, Kristin K. Zorn. (2007) Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecologic Oncology 106:3, 498-501
CrossRef287
David K. Gaffney, Kathryn Winter, Adam P. Dicker, Brigitte Miller, Patricia J. Eifel, Janice Ryu, Vilija Avizonis, Mitch Fromm, William Small, Kathryn Greven. (2007) Efficacy and Patterns of Failure for Locally Advanced Cancer of the Cervix Treated With Celebrex (Celecoxib) and Chemoradiotherapy in RTOG 0128. International Journal of Radiation Oncology*Biology*Physics 69:1, 111-117
CrossRef288
Robert Higgins, Mary Bussey, Wendel Naumann, James Hall, David Tait, Michael Haake. (2007) Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer. American Journal of Obstetrics and Gynecology 197:2, 205.e1-205.e7
CrossRef289
Luis A. Carrascosa, Catheryn M. Yashar, Kristie J. Paris, Renato V. Larocca, Samuel Ryan Faught, William J. Spanos. (2007) Palliation of Pelvic and Head and Neck Cancer with Paclitaxel and a Novel Radiotherapy Regimen. Journal of Palliative Medicine 10:4, 877-881
CrossRef290
Takashi Koyama, Ken Tamai, Kaori Togashi. (2007) Staging of carcinoma of the uterine cervix and endometrium. European Radiology 17:8, 2009-2019
CrossRef291
Chel Hun Choi, Jeong-Won Lee, Tae-Joong Kim, Woo Young Kim, Hee Rim Nam, Byoung-Gie Kim, Seung Jae Huh, Je-Ho Lee, Duk-Soo Bae. (2007) Phase II Study of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer: Preliminary Results. International Journal of Radiation Oncology*Biology*Physics 68:3, 817-822
CrossRef292
I.L. ATAHAN, F. YILDIZ, E. OZYAR, B. PEHLIVAN, M. GENC, M.F. KOSE, G. TULUNAY, A. AYHAN, K. YUCE, N. GULER, T. KUCUKALI. (2007) Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors. International Journal of Gynecological Cancer 17:4, 813-820
CrossRef293
William Small, Kathryn Winter, Charles Levenback, Revathy Iyer, David Gaffney, Sucha Asbell, Beth Erickson, Anuja Jhingran, Kathy Greven. (2007) Extended-Field Irradiation and Intracavitary Brachytherapy Combined With Cisplatin Chemotherapy for Cervical Cancer With Positive Para-Aortic or High Common Iliac Lymph Nodes: Results of ARM 1 of RTOG 0116. International Journal of Radiation Oncology*Biology*Physics 68:4, 1081-1087
CrossRef294
A. Poveda, R. Salazar, J. M. Campo, C. Mendiola, J. Cassinello, B. Ojeda, J. A. Arranz, A. Oaknin, J. García-Foncillas, M. J. Rubio, A. González Martín. (2007) Update in the management of ovarian and cervical carcinoma. Clinical and Translational Oncology 9:7, 443-451
CrossRef295
I.L. ATAHAN, C. ONAL, E. OZYAR, F. YILIZ, U. SELEK, F. KOSE. (2007) Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study. International Journal of Gynecological Cancer 17:4, 833-842
CrossRef296
David K. Gaffney, Andreas Du Bois, Kailash Narayan, Nick Reed, Takafumi Toita, Sandro Pignata, Peter Blake, Lorraine Portelance, Azmat Sadoyze, Richard Pötter, Alessandro Colombo, Marcus Randall, Mansoor R. Mirza, Edward L. Trimble. (2007) Practice Patterns of Radiotherapy in Cervical Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG). International Journal of Radiation Oncology*Biology*Physics 68:2, 485-490
CrossRef297
Akiva P. Novetsky, Mark H. Einstein, Gary L. Goldberg, Susan M. Hailpern, Evan Landau, Abbie L. Fields, Subhakar Mutyala, Shalom Kalnicki, Madhur Garg. (2007) Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer. Gynecologic Oncology 105:3, 635-640
CrossRef298
Jennifer F. De Los Santos, Gillian M. Thomas. (2007) Anemia correction in malignancy management: Threat or opportunity?. Gynecologic Oncology 105:2, 517-529
CrossRef299
Sushil Beriwal, Gregory N. Gan, Dwight E. Heron, Raj N. Selvaraj, Hayeon Kim, Ron Lalonde, Joseph L. Kelley, Robert P. Edwards. (2007) Early Clinical Outcome With Concurrent Chemotherapy and Extended-Field, Intensity-Modulated Radiotherapy for Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 68:1, 166-171
CrossRef300
Bradley J. Monk, Chunqiao Tian, Peter G. Rose, Rachelle Lanciano. (2007) Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma?. Gynecologic Oncology 105:2, 427-433
CrossRef301
G. Houvenaeghel, L. Lelievre, M. Buttarelli, J. Jacquemier, X. Carcopino, P. Viens, L. Gonzague-Casabianca. (2007) Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma. European Journal of Surgical Oncology (EJSO) 33:4, 498-503
CrossRef302
John Latimer. (2007) Gynaecological malignancies in pregnancy. Current Opinion in Obstetrics and Gynecology 19:2, 140-144
CrossRef303
Gabriella Ferrandina, Enrica Martinelli, Gian Franco Zannoni, Mariagrazia Distefano, Amelia Paglia, Cristiano Ferlini, Giovanni Scambia. (2007) Expression of class III β tubulin in cervical cancer patients administered preoperative radiochemotherapy: Correlation with response to treatment and clinical outcome. Gynecologic Oncology 104:2, 326-330
CrossRef304
Spyridon Tzioras, Nicholas Pavlidis, Evangelos Paraskevaidis, John P.A. Ioannidis. (2007) Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis. Cancer Treatment Reviews 33:1, 24-38
CrossRef305
Ludy Lutgens, Guido Lammering, Madelon Pijls-Johannesma, Jacoba van der Zee, Philippe Lambin, Dirk K M De Ruysscher, Jean-Marie Deneufbourg, Ludy Lutgens. 2007. Combined use of hyperthermia and radiation therapy for treating locally advanced cervical cancer. .
CrossRef306
Werner Dobrowsky, Nagraj G. Huigol, Ranapala S. Jayatilake, Noor-I-Alam Kizilbash, Sait Okkan, V. Tsutomu Kagiya, Hideo Tatsuzaki. (2007) AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: Results of an IAEA multicentre randomised trial. Radiotherapy and Oncology 82:1, 24-29
CrossRef307
Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Je-Ho Lee, Duk-Soo Bae. (2007) Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2–IIB cervical carcinoma. Gynecologic Oncology 104:1, 64-69
CrossRef308
Mark H. Einstein, Akiva P. Novetsky, Madhur Garg, Susan M. Hailpern, Gloria S. Huang, Arielle Glueck, Abbie L. Fields, Shalom Kalnicki, Gary L. Goldberg. (2007) Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer 109:1, 48-53
CrossRef309
Jonathan J. Beitler, Richard V. Smith, Randall P. Owen, Carl E. Silver, Madhu Mazumdar, Scott Wadler. (2007) Phase II clinical trial of parenteral hydroxyurea and hyperfractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: Toxicity and efficacy with continuous ribonucleoside reductase inhibition. Head & Neck 29:1, 18-25
CrossRef310
Me-Yeon Lee, Hong-Gyun Wu, Kyubo Kim, Sung Whan Ha, Jae Sung Kim, In Ah Kim, Hyo-Pyo Lee. (2007) Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix. Gynecologic Oncology 104:1, 95-99
CrossRef311
Myrna Candelaria, Lucely Cetina, Jaime de la Garza, Alfonso Dueñas-Gonzálz. (2007) Clinical implications of gemcitabine in the treatment of cervical cancer. European Journal of Cancer Supplements 5:1, 37-43
CrossRef312
Yong Bae Kim, Jae Ho Cho, Ki Chang Keum, Chang Geol Lee, Jinsil Seong, Chang Ok Suh, Gwi Eon Kim. (2007) Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. Gynecologic Oncology 104:1, 58-63
CrossRef313
Vutisiri Veerasarn, Vicharn Lorvidhaya, Pimkhuan Kamnerdsupaphon, Nan Suntornpong, Supatra Sangruchi, Prasert Lertsanguansinchai, Chonlakiet Khorprasert, Lak Sookpreedee, Suthipol Udompunturak. (2007) A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: Preliminary results. Gynecologic Oncology 104:1, 15-23
CrossRef314
Gilles Crehange, Mathieu Bosset, Fabrice Lorchel, Jean Luc Dumas, Joëlle Buffet-Miny, Marc Puyraveau, Mariette Mercier, Jean François Bosset. (2007) Combining Cisplatin and Mitomycin with Radiotherapy in Anal Carcinoma. Diseases of the Colon & Rectum 50:1, 43-49
CrossRef315
Anand Parthasarathy, Michael K. Cheung, Kathryn Osann, Amreen Husain, Nelson N. Teng, Jonathan S. Berek, Daniel S. Kapp, John K. Chan. (2006) The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecologic Oncology 103:3, 1095-1099
CrossRef316
Paul A. DiSilvestro, Joan L. Walker, Astrid Morrison, Peter G. Rose, Howard Homesley, David Warshal. (2006) Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the Gynecologic Oncology Group. Gynecologic Oncology 103:3, 1038-1042
CrossRef317
Y.G. Lin, M. Deavers, F. Sasan, J.S. Zager, L.M. Ramondetta. (2006) Clinical challenges presented by three simultaneous solid tumors. Gynecologic Oncology 103:3, 1159-1163
CrossRef318
S KEHOE. (2006) Treatments for gynaecological cancers. Best Practice & Research Clinical Obstetrics & Gynaecology 20:6, 985-1000
CrossRef319
Eduard Vrdoljak, Tomislav Omrčen, Žana Saratlija Novaković, Tihana Boraska Jelavić, Tomislav Prskalo, Dario Hrepić, Wolfgang Hamm. (2006) Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix—Final results of a prospective phase II-study. Gynecologic Oncology 103:2, 494-499
CrossRef320
Jason D. Wright, Dana Viviano, Matthew A. Powell, Randall K. Gibb, David G. Mutch, Perry W. Grigsby, Janet S. Rader. (2006) Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecologic Oncology 103:2, 489-493
CrossRef321
Gabriella Ferrandina, Mariagrazia Distefano, Daniela Smaniotto, Alessio Morganti, Amelia Paglia, Gabriella Macchia, Barbara Corvari, Domenica Lorusso, Giovanni Scambia. (2006) Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: Association with pathological response to treatment and clinical outcome. Gynecologic Oncology 103:2, 500-505
CrossRef322
Astrid Baalbergen, Anca Ansink, Lukas L Stalpers, Yerney Veenstra, Astrid Baalbergen. 2006. Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. .
CrossRef323
V. Kesic. (2006) Management of cervical cancer. European Journal of Surgical Oncology (EJSO) 32:8, 832-837
CrossRef324
Tatsuya Ohno, Shingo Kato, Masaru Wakatsuki, Shin-ei Noda, Chiemi Murakami, Misako Nakamura, Hirohiko Tsujii. (2006) Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: Comparison with radiation therapy alone. Gynecologic Oncology 103:1, 94-99
CrossRef325
Vandana Keskar, Prem S. Mohanty, Ernest J. Gemeinhart, Richard A. Gemeinhart. (2006) Cervical cancer treatment with a locally insertable controlled release delivery system. Journal of Controlled Release 115:3, 280-288
CrossRef326
R MARTINEZMONGE, M JURADO, M CAMBEIRO, J VALERO, E VILLAFRANCA, J ALCAZAR. (2006) Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecologic cancer: Initial results of a phase II trial. Brachytherapy 5:4, 203-210
CrossRef327
Takafumi Toita. (2006) Concurrent chemoradiation for cervical cancer: what should we do next?. International Journal of Clinical Oncology 11:4, 253-255
CrossRef328
Yoh Watanabe, Hidekatsu Nakai, Masao Shimaoka, Takako Tobiume, Isao Tsuji, Hiroshi Hoshiai. (2006) Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. International Journal of Clinical Oncology 11:4, 309-313
CrossRef329
Setsuko Kawase, Takahito Okuda, Mitsuru Ikeda, Shunichi Ishihara, Yoshiyuki Itoh, Shigeo Yanagawa, Takeo Ishigaki. (2006) Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radiation therapy for patients with high-risk uterine cervical cancer. Gynecologic Oncology 102:3, 493-499
CrossRef330
Kristina Gerszten, William E. Gooding, Yan Lin, Dwight E. Heron, Clare Faul. (2006) A single institutional experience with definitive radiotherapy for cervical cancer using both high- and low-dose-rate brachytherapy. Gynecologic Oncology 102:3, 500-507
CrossRef331
C. H. Cho, P. Wust, B. Hildebrandt, J. Gellermann. (2006) Neue Behandlungsansätze mit Hyperthermie bei Zervixkarzinomen. Der Onkologe 12:9, 923-930
CrossRef332
S.M. TEMKIN, M. HELLMANN, E. SERUR, Y.-C. LEE, O. ABULAFIA. (2006) Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. International Journal of Gynecological Cancer 16:5, 1855-1861
CrossRef333
Y.S. CHOI, C.M. YI, J.-I. SIN, G.W. YE, I.H. SHIN, T.S. LEE. (2006) Impact of hemoglobin on survival of cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imaging. International Journal of Gynecological Cancer 16:5, 1846-1854
CrossRef334
G. Hänsgen. (2006) Radiochemotherapie beim Zervixkarzinom. Der Onkologe 12:9, 917-922
CrossRef335
Frank J.P. Hoebers, Dick Pluim, Marcel Verheij, Alfons J.M. Balm, Harry Bartelink, Jan H.M. Schellens, Adrian C. Begg. (2006) Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). International Journal of Cancer 119:4, 750-756
CrossRef336
Kristina Gerszten, Kelly Colonello, Dwight E. Heron, Ron J. Lalonde, Issa D. Fitian, John T. Comerci, Raj N. Selvaraj, John M. Varlotto. (2006) Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix. Gynecologic Oncology 102:2, 182-188
CrossRef337
Jianli Hu, Shiying Yu, Huihua Xiong, Xianglin Yuan. (2006) Gemcitabine modulates the microvessel density and apoptosis in radiotherapy of cervical cancer. The Chinese-German Journal of Clinical Oncology 5:4, 282-284
CrossRef338
C. NYONGESA, P. RUFF, B. DONDE, J. KOTZEN. (2006) A phase I study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy. International Journal of Gynecological Cancer 16:4, 1614-1619
CrossRef339
Gilles Houvenaeghel, Loic Lelievre, Anne-Laure Rigouard, Max Buttarelli, Jocelyne Jacquemier, Patrice Viens, Laurence Gonzague-Casabianca. (2006) Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer. Gynecologic Oncology 102:1, 74-79
CrossRef340
Elizabeth M. Swisher, Ron E. Swensen, Benjamin Greer, Hisham Tamimi, Barbara A. Goff, Rochelle Garcia, Wui-jin Koh. (2006) Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: A phase I trial of the Puget Sound Oncology Consortium. Gynecologic Oncology 101:3, 429-435
CrossRef341
John M. Varlotto, Kristina Gerszten, Dwight E. Heron, John Comerci, Shiva Gautam, Raj Selvaraj, Ron Lalonde, Justin C. Chura. (2006) The Potential Nephrotoxic Effects of Intensity Modulated Radiotherapy Delivered to the Para-Aortic Area of Women With Gynecologic Malignancies. American Journal of Clinical Oncology 29:3, 281-289
CrossRef342
Kyubo Kim, Eui Kyu Chie, Hong-Gyun Wu, Sung W. Ha, Jae Sung Kim, In Ah Kim, Hyo-Pyo Lee. (2006) Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecologic Oncology 101:3, 398-402
CrossRef343
Kiichiro Noda, Yasuo Ohashi, Hajime Sugimori, Masami Ozaki, Hideo Niibe, Sachio Ogita, Ichiro Kohno, Kazuo Hasegawa, Yuzo Kikuchi, Yoshihiro Takegawa, Shingo Fujii, Kenichi Tanaka, Kazunori Ochiai, Midori Kita, Keiichi Fujiwara. (2006) Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: Treatment with immunomodulator, more is not better. Gynecologic Oncology 101:3, 455-463
CrossRef344
T-J Kim, J-W Lee, S Y Song, J-J Choi, C H Choi, B-G Kim, J-H Lee, D-S Bae. (2006) Increased expression of pAKT is associated with radiation resistance in cervical cancer. British Journal of Cancer
CrossRef345
David H. Moore. (2006) Cervical Cancer. Obstetrics & Gynecology 107:5, 1152-1161
CrossRef346
N.R. Datta, S. Agrawal. (2006) Does the Evidence Support the Use of Concurrent Chemoradiotherapy as a Standard in the Management of Locally Advanced Cancer of the Cervix, Especially in Developing countries?. Clinical Oncology 18:4, 306-312
CrossRef347
Muneaki Shimada, Junzo Kigawa, Ryuichiro Nishimura, Satoshi Yamaguchi, Kazuo Kuzuya, Toru Nakanishi, Mitsuaki Suzuki, Tsunekazu Kita, Tsuyoshi Iwasaka, Naoki Terakawa. (2006) Ovarian metastasis in carcinoma of the uterine cervix. Gynecologic Oncology 101:2, 234-237
CrossRef348
L. GOEDHALS, A.L. van WIYK, B.L. SMITH, S.J. FOURIE. (2006) Pemetrexed (AlimtaR, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. International Journal of Gynecological Cancer 16:3, 1172-1178
CrossRef349
J. Sehouli, W. Lichtenegger. (2006) Aktuelles Management des Zervixkarzinoms. Der Gynäkologe 39:5, 379-394
CrossRef350
J.P. MICHA, B.H. GOLDSTEIN, M.A. RETTENMAIER, J.V. BROWN, C.R. JOHN, M. MARKMAN. (2006) Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma. International Journal of Gynecological Cancer 16:3, 1147-1151
CrossRef351
Patricia J Eifel. (2006) Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nature Clinical Practice Oncology 3:5, 248-255
CrossRef352
J. Michael Straughn, Patsy G. Oliver, Tong Zhou, Wenquan Wang, Ronald D. Alvarez, William E. Grizzle, Donald J. Buchsbaum. (2006) Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecologic Oncology 101:1, 46-54
CrossRef353
Kristin A. Bradley, Daniel G. Petereit. (2006) Radiation Therapy for Gynecologic Malignancies. Hematology/Oncology Clinics of North America 20:2, 347-361
CrossRef354
D. FINK, N. CHETTY, J.P. LEHM, D.E. MARSDEN, N.F. HACKER. (2006) Hyperbaric oxygen therapy for delayed radiation injuries in gynecological cancers. International Journal of Gynecological Cancer 16:2, 638-642
CrossRef355
L. SELVAGGI, V. LOIZZI, A. R. DI GILIO, C. NARDELLI, C. CANTATORE, G. CORMIO. (2006) Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience. International Journal of Gynecological Cancer 16:2, 631-637
CrossRef356
M. King, C. McConkey, T.N. Latief, A. Hartley, I. Fernando. (2006) Improved Survival After Concurrent Weekly Cisplatin and Radiotherapy for Cervical Carcinoma with Assessment of Acute and Late Side-effects. Clinical Oncology 18:1, 38-45
CrossRef357
C.T. Thomas, A. Ammar, J.J. Farrell, H. Elsaleh. (2006) Radiation Modifiers: Treatment Overview and Future Investigations. Hematology/Oncology Clinics of North America 20:1, 119-139
CrossRef358
Cheryl A. Brewer, John A. Blessing, Robert A. Nagourney, D. Scott McMeekin, Shashikant Lele, Susan L. Zweizig. (2006) Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Gynecologic Oncology 100:2, 385-388
CrossRef359
Gilles Houvenaeghel, Loic Lelievre, Laurence Gonzague-Casabianca, Max Buttarelli, Vincent Moutardier, Anthony Goncalves, Michel Resbeut. (2006) Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecologic Oncology 100:2, 338-343
CrossRef360
Milica MARKOVIC, Lenore MANDERSON, Michael QUINN. (2006) Treatment decisions: A qualitative study with women with gynaecological cancer. The Australian and New Zealand Journal of Obstetrics and Gynaecology 46:1, 46-48
CrossRef361
Rakesh R. Patel, Douglas W. Arthur. (2006) The Emergence of Advanced Brachytherapy Techniques for Common Malignancies. Hematology/Oncology Clinics of North America 20:1, 97-118
CrossRef362
M.V. Williams, N.D. James, E.T. Summers, A. Barrett, D.V. Ash. (2006) National Survey of Radiotherapy Fractionation Practice in 2003. Clinical Oncology 18:1, 3-14
CrossRef363
M.C. Fernández-Fernández, J.C. Fernández-Fernández, M.J. Jiménez-Torres, J.A. Vargas. (2006) Radioquimioterapia en el carcinoma localmente avanzado de cérvix. Clínica e Investigación en Ginecología y Obstetricia 33:1, 2-6
CrossRef364
Hitoshi Ikushima, Kyousuke Osaki, Shunsuke Furutani, Kyou Yamashita, Takashi Kawanaka, Yoshiomi Kishida, Seiji Iwamoto, Yoshihiro Takegawa, Takaharu Kudoh, Hiromu Nishitani. (2006) Chemoradiation therapy for cervical cancer: Toxicity of concurrent weekly cisplatin. Radiation Medicine 24:2, 115-121
CrossRef365
Youn Seok Choi, Jeong-Im Sin, Ju Hyun Kim, Gi Won Ye, Im Hee Shin, Tae Sung Lee. (2006) Survival Benefits of Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy in Locally Advanced Chemoresistant Cervical Cancer. Journal of Korean Medical Science 21:4, 683
CrossRef366
Amnon Amit, Dan Beck, Lior Lowenstein, Offer Lavie, Rachel Bar shalom, Zohar Kedar, Ora Israel. (2006) The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecologic Oncology 100:1, 65-69
CrossRef367
T.P. SHAKESPEARE, K.H.C. LIM, K.M. LEE, M.F. BACK, R. MUKHERJEE, J.D. LU. (2006) Phase II study of the American Brachytherapy Society guidelines for the use of high-dose rate brachytherapy in the treatment of cervical carcinoma: is 45-50.4 Gy radiochemotherapy plus 31.8 Gy in six fractions high-dose rate brachytherapy tolerable?. International Journal of Gynecological Cancer 16:1, 277-282
CrossRef368
L. Miglietta, P. Franzone, M.G. Centurioni, L. Boni, L. Tacchini, M. Cosso, F. Boccardo, M. Ferrarini, M. Bruzzone. (2006) A Phase II Trial with Cisplatin-Paclitaxel Cytotoxic Treatment and Concurrent External and Endocavitary Radiation Therapy in Locally Advanced or Recurrent Cervical Cancer. Oncology 70:1, 19-24
CrossRef369
J. Umanzor, M. Aguiluz, C. Pineda, S. Andrade, M. Erazo, Claudio Flores, Sergio Santillana. (2006) Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: A phase II trial. Gynecologic Oncology 100:1, 70-75
CrossRef370
YOKO HARIMA, TOSHIKO SHIGA, MINORU KAMATA, HIROYUKI KOJIMA, SIGEKI IKEDA, SATOSHI SAWADA. (2006) Thermoradiotherapy in Advanced Cervical Cancer: Clinical Experiments and Molecular Research. Thermal Medicine 22:3, 141-150
CrossRef371
Distefano Mariagrazia, Fagotti Anna, Ferrandina Gabriella, Fanfani Francesco, Smaniotto Daniela, D'Agostino Giuseppe, Morganti Alessio, Scambia Giovanni. (2005) Preoperative chemoradiotherapy in locally advanced cervical cancer: Long-term outcome and complications. Gynecologic Oncology 99:3, S166-S170
CrossRef372
Krishnansu S. Tewari, Bradley J. Monk. (2005) Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Current Oncology Reports 7:6, 419-434
CrossRef373
Isabelle Cadron, Frederic Amant, Ignace Vergote. (2005) Chemotherapy for cervical cancer. European Clinics in Obstetrics and Gynaecology 1:3, 143-150
CrossRef374
Catheryn M. Yashar, William J. Spanos, Douglas D. Taylor, Cicek Gercel-Taylor. (2005) Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecologic Oncology 99:1, 199-205
CrossRef375
Francisco José Andreu-Martínez, Julia M. Martínez-Mateu. (2005) Hypoxia and anaemia in patients with cancer of the uterine cervix. Clinical and Translational Oncology 7:8, 323-331
CrossRef376
E.P. SAIBISHKUMAR, F.D. PATEL, S.C. SHARMA. (2005) Results of radiotherapy alone in the treatment of carcinoma of uterine cervix: a retrospective analysis of 1069 patients. International Journal of Gynecological Cancer 15:5, 890-897
CrossRef377
Luis A Rojas-Espaillat, Peter G Rose. (2005) Management of locally advanced cervical cancer. Current Opinion in Oncology 17:5, 485-492
CrossRef378
Anneke M. Westermann, Ellen L. Jones, Baard-Christian Schem, Elzbieta M. van der Steen-Banasik, Peter Koper, Olav Mella, Apollonia L. J. Uitterhoeve, Ronald de Wit, Jacobus van der Velden, Curt Burger, Clasina L. van der Wilt, Olav Dahl, Leonard R. Prosnitz, Jacoba van der Zee. (2005) First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma. Cancer 104:4, 763-770
CrossRef379
G. Dreyer. (2005) Operative management of cervical cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 19:4, 563-576
CrossRef380
D. Allen, K. Narayan. (2005) Managing advanced-stage cervical cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 19:4, 591-609
CrossRef381
John A Green, John J Kirwan, Jayne Tierney, Claire L Vale, Paul R Symonds, Lydia L Fresco, Chris Williams, Mandy Collingwood, John Green. 2005. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. .
CrossRef382
K. NARAYAN. (2005) Arguments for a magnetic resonance imaging-assisted FIGO staging system for cervical cancer. International Journal of Gynecological Cancer 15:4, 573-582
CrossRef383
Masakazu Nishida, Kaei Nasu, Noriyuki Takai, Isao Miyakawa, Kenji Kashima. (2005) Adenoid cystic carcinoma of the uterine cervix. International Journal of Clinical Oncology 10:3, 198-200
CrossRef384
Koichi Isobe, Takashi Uno, Takashi Aruga, Hiroyuki Kawakami, Naoyuki Ueno, Toyoyuki Hanazawa, Yoshitaka Okamoto, Hisao Ito. (2005) Weekly cisplatin administration concurrent with radiation therapy for locoregionally advanced nasopharyngeal carcinoma. International Journal of Clinical Oncology 10:3, 201-203
CrossRef385
Krystyna Serkies, Jacek Jassem. (2005) Chemotherapy in the primary treatment of cervical carcinoma. Critical Reviews in Oncology/Hematology 54:3, 197-208
CrossRef386
Shalini Singh, Niloy R. Datta, Narendra Krishnani, Punita Lal, Shaleen Kumar. (2005) Radiation therapy induced micronuclei in cervical cancer—does it have a predictive value for local disease control?. Gynecologic Oncology 97:3, 764-771
CrossRef387
J.A. de Hullu, E. Pras, H. Hollema, A.G.J. van der Zee, D.H. Bogchelman, M.J.E. Mourits. (2005) Presentations of endometrial activity after curative radiotherapy for cervical cancer. Maturitas 51:2, 172-176
CrossRef388
Zuzana Stokes, Paul Symonds, Tim Habeshaw, Nick Reed, Jorge Curto, Claire Joynson, Steve Chan. (2005) Phase one dose finding study of capecitabine (Xeloda®), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer. Gynecologic Oncology 97:3, 790-795
CrossRef389
Diane C. Bodurka, Charlotte C. Sun, Michael M. Frumovitz. (2005) Quality of life in cervix cancer survivors—What matters the most in the long-term?. Gynecologic Oncology 97:2, 307-309
CrossRef390
R. Rouzier, P. Morice, R. De Crevoisier, C. Pomel, A. Rey, K. Bonnet, A. Recoules-Arche, P. Duvillard, C. Lhomme, C. Haie-Meder, D. Castaigne. (2005) Survival in cervix cancer patients treated with radiotherapy followed by radical surgery. European Journal of Surgical Oncology (EJSO) 31:4, 424-433
CrossRef391
D.K. Gaffney, K. Winter, C. Fuhrman, R. Flinner, K. Greven, J. Ryu, A. Forbes, K. Kerlin, R.C. Nichols, K. Zempolich. (2005) Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128. Gynecologic Oncology 97:2, 607-611
CrossRef392
W. Termrungruanglert, D. Tresukosol, A. Vasuratna, T. Sittisomwong, R. Lertkhachonsuk, N. Sirisabya. (2005) Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2. Gynecologic Oncology 97:2, 576-581
CrossRef393
Elie Azria, Philippe Morice, Christine Haie-Meder, Anne Thoury, Patricia Pautier, Catherine Lhomme, Pierre Duvillard, Damienne Castaigne. (2005) Results of Hysterectomy in Patients With Bulky Residual Disease at the End of Chemoradiotherapy for Stage IB2/II Cervical Carcinoma. Annals of Surgical Oncology 12:4, 332-337
CrossRef394
Yih-Lin Chung, James Jer-Min Jian, Skye Hongiun Cheng, Cheng-I Hsieh, Tran-Der Tan, Hui-Ju Chang, Chi-Feng Hung, Cheng-Fang Horng, Thomas Soong, Mei-Hua Tsou. (2005) Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study. Gynecologic Oncology 97:1, 126-135
CrossRef395
A DUENASGONZALEZ, L CETINAPEREZ, L ONATEOCANA, L RIVERA, C LOPEZGRANIEL, A GONZALEZENCISO, M CANDELARIA, A MOHAR. (2005) Multimodal Treatment of Locally Advanced Cervical Cancer. Archives of Medical Research 36:2, 129-135
CrossRef396
Philip Robinson, Denise Stuber, Fran
ois Deryck
CrossRef397
A. Ercoli, G. Ferrandina, M. Genuardi, G.F. Zannoni, L. Cicchillitti, G. Raspaglio, S. Carrara, S. Mancuso, G. Scambia. (2005) Microsatellite instability is not related to response to cisplatin-based chemotherapy in cervical cancer. International Journal of Gynecological Cancer 15:2, 308-311
CrossRef398
Shoji Nagao, Keiichi Fujiwara, Takashi Oda, Hiroyasu Ishikawa, Hirofumi Koike, Hiromasa Tanaka, Ichiro Kohno. (2005) Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecologic Oncology 96:3, 805-809
CrossRef399
Bradley J. Monk, Jianmin Wang, Samuel Im, Richard J. Stock, William A. Peters, P.Y. Liu, Rolland J. Barrett, Jonathan S. Berek, Luis Souhami, Perry W. Grigsby, William Gordon, David S. Alberts. (2005) Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical–pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecologic Oncology 96:3, 721-728
CrossRef400
Takafumi Toita, Hidehiko Moromizato, Kazuhiko Ogawa, Yasumasa Kakinohana, Toshiyuki Maehama, Koji Kanazawa, Sadayuki Murayama. (2005) Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. Gynecologic Oncology 96:3, 665-670
CrossRef401
Wendy R. Brewster. (2005) Untreated Cervical Cancer. Gynecologic Oncology 96:2, 269-270
CrossRef402
Takashi Uno, Hisao Ito, Koichi Isobe, Yuko Kaneyasu, Naotake Tanaka, Akira Mitsuhashi, Kiyomi Suzuka, Koji Yamazawa, Naoyuki Shigematsu, Jun Itami. (2005) Postoperative pelvic radiotherapy for cervical cancer patients with positive parametrial invasion. Gynecologic Oncology 96:2, 335-340
CrossRef403
Jin Ho Kim, Hak Jae Kim, Semie Hong, Hong-Gyun Wu, Sung Whan Ha. (2005) Post-hysterectomy radiotherapy in FIGO stage IB–IIB uterine cervical carcinoma. Gynecologic Oncology 96:2, 407-414
CrossRef404
Annie Yessaian, Alberto A. Mendivil, Wendy R. Brewster. (2005) Population characteristics in cervical cancer trials: Search for external validity. American Journal of Obstetrics and Gynecology 192:2, 407-413
CrossRef405
Hee-Sug Ryu, Mison Chun, Ki-Hong Chang, Hye-Jin Chang, Jung-Pil Lee. (2005) Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecologic Oncology 96:2, 490-495
CrossRef406
Takashi Nakano, Shingo Kato, Tatsuya Ohno, Hirohiko Tsujii, Shinichiro Sato, Kenjiro Fukuhisa, Tatsuo Arai. (2005) Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer 103:1, 92-101
CrossRef407
Maurie Markman. (2005) Reflections on Ethical Concerns Arising from the Incorporation of Results of Randomized Trials of Antineoplastic Therapy into Routine Clinical Practice. Cancer Investigation 23:8, 735-740
CrossRef408
Daniel T Rein, Peter Dall, Christian M Kurbacher, Martina Breidenbach. (2005) Developments and Current Treatment Standards in Cervical Cancer. American Journal of Cancer 4:6, 373-381
CrossRef409
Young Seok Kim, Seong Soo Shin, Eun Kyung Choi, Jong Hoon Kim, Seung Do Ahn, Sang-wook Lee, Heon-Jin Park, Young-Tak Kim, Jung-Eun Mok, Joo-Hyun Nam. (2005) A Preliminary Results of a Randomized Trial Comparing Monthly 5-flourouracil and Cisplatin to W eekly Cisplatin A lone Combined with Concurrent Radiotherapy for Locally Advanced Cervical Cancer. Cancer Research and Treatment 37:1, 37
CrossRef410
Gabriele K. Beckmann, Florian Hoppe, Leo Pfreundner, Michael P. Flentje. (2005) Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head & Neck 27:1, 36-43
CrossRef411
Aljosa Mandic. (2005) Neoadjuvant chemotherapy in treatment of cervical cancer: Controversies. Archive of oncology 13:2, 89-90
CrossRef412
Shujiro B. Minami, Su-Hua Sha, Jochen Schacht. (2004) Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hearing Research 198:1-2, 137-143
CrossRef413
Juan E. Sardi, María A. Boixadera, Juan J. Sardi. (2004) A critical overview of concurrent chemoradiotherapy in cervical cancer. Current Oncology Reports 6:6, 463-470
CrossRef414
Jennifer F. De Los Santos, William Small. (2004) The role of amifostine in the treatment of carcinoma of the uterine cervix: An update of RTOG-0116 and review of future directions. Seminars in Oncology 31, 37-41
CrossRef415
Satoru Motoyama, Shinya Hamana, Yonson Ku, Jovelle B. Laoag-Fernandez, Masashi Deguchi, Shigeki Yoshida, Masahiro Tominaga, Takeshi Iwasaki, Noriyuki Ohara, Takeshi Maruo. (2004) Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa–IVa cervical cancer. Gynecologic Oncology 95:3, 576-582
CrossRef416
Pascal Gervaz, Abdelkarim S Allal, Arnaud Roth, Philippe Morel. (2004) Chemotherapeutic options in the management of anal cancer. Expert Opinion on Pharmacotherapy 5:12, 2479-2484
CrossRef417
Franco M. Muggia. (2004) Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Seminars in Oncology 31, 17-24
CrossRef418
N.R. Datta, R. Pasricha, U. Singh, A. Srivastava. (2004) Predictors of survival end points in patients with cancer of the cervix on long-term follow-up: inferences and implications from an audit of patients treated with a specific radiotherapy protocol. Clinical Oncology 16:8, 536-542
CrossRef419
Rashmi Singh, Nick D. James, Nick A. Watkin. (2004) Future development of penile cancer services in the UK. BJU International 94:7, 967-969
CrossRef420
Robert S. Lavey, P.Y. Liu, Benjamin E. Greer, William R. Robinson, Pui C. Chang, Raymond B. Wynn, Marcel E. Conrad, Caroline Jiang, Maurie Markman, David S. Alberts. (2004) Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB–IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecologic Oncology 95:1, 145-151
CrossRef421
Rosa Tambaro, Giovanni Scambia, Massimo Di Maio, Carmela Pisano, Emiddio Barletta, Vincenzo Rosario Iaffaioli, Sandro Pignata. (2004) The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Critical Reviews in Oncology/Hematology 52:1, 33-44
CrossRef422
Shang-Wen Chen, Ji-An Liang, Shih-Neng Yang, Yao-Ching Hung, Lian-Shung Yeh, An-Cheng Shiau, Fang-Jen Lin. (2004) Radiation injury to intestine following hysterectomy and adjuvant radiotherapy for cervical cancer. Gynecologic Oncology 95:1, 208-214
CrossRef423
S. K
CrossRef424
Jafaru I Abu, David Nunns, Quentin Davies, David Ireland. (2004) The current management of cervical cancer. The Obstetrician & Gynaecologist 6:4, 196-202
CrossRef425
Ren
CrossRef426
P. W. Grigsby. (2004) Prospective phase I/II study of irradiation and concurrent chemotherapy for recurrent cervical cancer after radical hysterectomy. International Journal of Gynecological Cancer 14:5, 860-864
CrossRef427
Maurie Markman. (2004) Translating the results of phase III randomized cancer trials into the language of physician obligation to patients. Current Oncology Reports 6:4, 243-244
CrossRef428
R.P Symonds, M Collingwood, J Kirwan, C.E Humber, J.F Tierney, J.A Green, C Williams. (2004) Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review. Cancer Treatment Reviews 30:5, 405-414
CrossRef429
William E Winter, G.Larry Maxwel, Chunqiao Tian, Eugene Sobel, G Scott Rose, Gillian Thomas, Jay W Carlson. (2004) Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecologic Oncology 94:2, 495-501
CrossRef430
Melissa A. Decker, James J. Burke, Donald G. Gallup, Robert W. Silverio, David Weems, John Duttenhaver, Dent Purcell. (2004) Completion hysterectomy after radiation therapy for bulky cervical cancer stages IB, IIA, and IIB: Complications and survival rates. American Journal of Obstetrics and Gynecology 191:2, 654-658
CrossRef431
(2004) Discussion. American Journal of Obstetrics and Gynecology 191:2, 658-660
CrossRef432
Rachel A Dubay, Peter G Rose, David M O'Malley, Abdelwahab D Shalodi, Adir Ludin, Mostafa A Selim. (2004) Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecologic Oncology 94:1, 121-124
CrossRef433
Annie Yessaian, Alessandra Magistris, Robert A Burger, Bradley J Monk. (2004) Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecologic Oncology 94:1, 61-66
CrossRef434
Juan Luis Alc
CrossRef435
Ayman Saad, Simon S. Lo, Ihn Han, Sameer Keole, Charles P. Lee, Sam Tekyi-Mensah, Adnan Munkarah, John Malone, Robert Morris, Gunter Deppe. (2004) Radiation Therapy With or Without Chemotherapy for Cervical Cancer With Periaortic Lymph Node Metastasis. American Journal of Clinical Oncology 27:3, 256-263
CrossRef436
L.T. Tan, S. Russell, L. Burgess. (2004) Acute Toxicity of Chemo-radiotherapy for Cervical Cancer: The Addenbrooke’s Experience. Clinical Oncology 16:4, 255-260
CrossRef437
Margrit M Juretzka, Kristin C Jensen, Teri A Longacre, Nelson N Teng, Amreen Husain. (2004) Detection of pelvic lymph node micrometastasis in stage IA2–IB2 cervical cancer by immunohistochemical analysis. Gynecologic Oncology 93:1, 107-111
CrossRef438
Emmanuel Barranger, Annie Cortez, Dany Grahek, Patrice Callard, Serge Uzan, Emile Darai. (2004) Laparoscopic Sentinel Node Procedure for Cervical Cancer: Impact of Neoadjuvant Chemoradiotherapy. Annals of Surgical Oncology 11:4, 445-452
CrossRef439
Hemant B Tongaonkar. (2004) Changing practice of gynecologic oncology based on current evidence. Medical Journal Armed Forces India 60:2, 102-106
CrossRef440
Andreas Widschwendter, Lennart Ivarsson, Anya Blassnig, Hannes M. M
CrossRef441
Saban Cakir, Ibrahim Egehan. (2004) A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43:3, 309-316
CrossRef442
A. Ayhan, R. A. Al, C. Baykal, E. Demirtas, A. Ayhan, K. Yuce. (2004) Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy. International Journal of Gynecological Cancer 14:2, 286-292
CrossRef443
Arno J Mundt, Jacob Rotmensch, Steven E Waggoner, S.Diane Yamada, Gini F Fleming. (2004) Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecologic Oncology 92:3, 801-805
CrossRef444
John O. Schorge, Lynne M. Knowles, Jayanthi S. Lea. (2004) Adenocarcinoma of the cervix. Current Treatment Options in Oncology 5:2, 119-127
CrossRef445
Jonathan Markman, Kristine Zanotti, Kenneth Webster, Jerome Belinson, Gertrude Peterson, Barbara Kulp, Maurie Markman. (2004) Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecologic Oncology 92:2, 592-595
CrossRef446
Michiko Aoki, Jun-ichi Akahira, Hitoshi Niikura, Sumika Saito, Yoriko Abe, Takeshi Aida, Naoko Sato, Takako Kitamura, Kenro Otsuki, Atsuko Katahira, Hiroki Utsunomiya, Chikako Okamura, Tadao Takano, Kiyoshi Ito, Kunihiro Okamura, Nobuo Yaegashi. (2004) Retrospective Analysis of Concurrent Chemoradiation with the Combination of Bleomycin, Ifosfamide and Cisplatin (BIP) for Uterine Cervical Cancer. The Tohoku Journal of Experimental Medicine 204:4, 309-315
CrossRef447
Mariagrazia Distefano, Gabriella Ferrandina, Daniela Smaniotto, Alessandro Pasquale Margariti, Gianfranco Zannoni, Gabriella Macchia, Riccardo Manfredi, Maria Grazia Mangiacotti, Numa Cellini, Giovanni Scambia. (2004) Concomitant Radiochemotherapy plus Surgery in Locally Advanced Cervical Cancer: Update of Clinical Outcome and Cyclooxygenase-2 as Predictor of Treatment Susceptibility. Oncology 67:2, 103-111
CrossRef448
S. M. Eisenkop, N. M. Spirtos. (2004) The relative importance of surgical training and laboratory research in a gynecologic oncology fellowship. International Journal of Gynecological Cancer 14:1, 23-34
CrossRef449
John A Green, Alberto de Barros Lopes. (2004) Optimizing Treatment for Cervical Cancer. American Journal of Cancer 3:4, 215-227
CrossRef450
Taek Keun Nam, Sung Ja Ahn. (2004) A Prospective Randomized Study on Two Dose Fractionation Regimens of High-Dose-Rate Brachytherapy for Carcinoma of the Uterine Cervix: Comparison of Efficacies and Toxicities Between Two Regimens. Journal of Korean Medical Science 19:1, 87
CrossRef451
Takeshi Kodaira, Nobukazu Fuwa, Takafumi Toita, Yoshihito Nomoto, Kazuo Kuzuya, Kazuyuki Tachibana, Kazuhisa Furutani, Kazuhiko Ogawa. (2003) Clinical Evaluation Using Magnetic Resonance Imaging for Patients With Stage III Cervical Carcinoma Treated by Radiation Alone in Multicenter Analysis. American Journal of Clinical Oncology 26:6, 574-583
CrossRef452
J.H Maduro, E Pras, P.H.B Willemse, E.G.E de Vries. (2003) Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treatment Reviews 29:6, 471-488
CrossRef453
William Small. (2003) Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the radiation therapy oncology group C-0116 trial. Seminars in Oncology 30, 68-71
CrossRef454
D.M Kecmanovic, M.J Pavlov, P.A Kovacevic, A.V Sepetkovski, M.S Ceranic, A.B Stamenkovic. (2003) Management of advanced pelvic cancer by exenteration. European Journal of Surgical Oncology (EJSO) 29:9, 743-746
CrossRef455
Harry J. Long. (2003) Current research directions for locally advanced cervix cancer. Current Oncology Reports 5:6, 468-472
CrossRef456
Frederick B. Stehman, Peter G. Rose, Benjamin E. Greer, Michel Roy, Marie Plante, Manuel Penalver, Anuja Jhingran, Patricia Eifel, Fredrick Montz, J. Taylor Wharton. (2003) Innovations in the treatment of invasive cervical cancer. Cancer 98:S9, 2052-2063
CrossRef457
Maurie Markman. (2003) Toxicities of the platinum antineoplastic agents. Expert Opinion on Drug Safety 2:6, 597-607
CrossRef458
Carlos T. Vallejo, Mario R. Machiavelli, Juan E. P??rez, Alberto O. Romero, Fabrina Bologna, Hern??n Vicente, Juan A. Lacava, Eduardo H. Ortiz, Alberto Cubero, Guillermo Focaccia, Guillermo Suttora, Mirna Scenna, Jos?? M. Boughen, Bernardo A. Leone. (2003) Docetaxel as Neoadjuvant Chemotherapy in Patients With Advanced Cervical Carcinoma. American Journal of Clinical Oncology 26:5, 477-482
CrossRef459
David H Moore. (2003) Treatment of stage IB2 (bulky) cervical carcinoma. Cancer Treatment Reviews 29:5, 401-406
CrossRef460
Alfonso Dueñas-Gonzalez, Lucely Cetina, Ignacio Mariscal, Jaime de la Garza. (2003) Modern management of locally advanced cervical carcinoma. Cancer Treatment Reviews 29:5, 389-399
CrossRef461
V. Loizzi, G. Cormio, G. Loverro, L. Selvaggi, P. J. Disaia, F. Cappuccini. (2003) Chemoradiation: A new approach for the treatment of cervical cancer. International Journal of Gynecological Cancer 13:5, 580-586
CrossRef462
A. Obermair, R. Cheuk, K. Horwood, M. Neudorfer, M. Janda, G. Giannis, J.L. Nicklin, L.C. Perrin, A.J. Crandon. (2003) Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. International Journal of Gynecological Cancer 13:5, 633-639
CrossRef463
Tate Thigpen. (2003) The Role of Chemotherapy in the Management of Carcinoma of the Cervix. The Cancer Journal 9:5, 425-432
CrossRef464
S. Wilailak, S. Dangprasert, S. Srisupundit. (2003) Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients. International Journal of Gynecological Cancer 13:5, 652-656
CrossRef465
James V. Fiorica. (2003) The role of topotecan in the treatment of advanced cervical cancer. Gynecologic Oncology 90:3, S16-S21
CrossRef466
Jeanne M. Schilder, Frederick B. Stehman. (2003) Stage Ia-IIa Cancer of the Cervix. The Cancer Journal 9:5, 395-403
CrossRef467
Peter G. Rose. (2003) Stage IIB-IVA Cancer of the Cervix. The Cancer Journal 9:5, 404-414
CrossRef468
Thomas J Herzog. (2003) New approaches for the management of cervical cancer. Gynecologic Oncology 90:3, S22-S27
CrossRef469
S. Sundar, P. Symonds, C. Deehan. (2003) Tolerance of Pelvic Organs to Radiation Treatment for Carcinoma of Cervix. Clinical Oncology 15:5, 240-247
CrossRef470
Ellen L. Jones, Thaddeus V. Samulski, Mark W. Dewhirst, Angeles Alvarez-Secord, Andrew Berchuck, Daniel Clarke-Pearson, Laura J. Havrilesky, John Soper, Leonard R. Prosnitz. (2003) A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer 98:2, 277-282
CrossRef471
Evelyne L Weaver, Rathindra N Bose. (2003) Platinum(II) catalysis and radical intervention in reductions of platinum(IV) antitumor drugs by ascorbic acid. Journal of Inorganic Biochemistry 95:4, 231-239
CrossRef472
Emmanuel Barranger, Dany Grahek, Annie Cortez, Jean Noel Talbot, Serge Uzan, Emile Darai. (2003) Laparoscopic sentinel lymph node procedure using a combination of patent blue and radioisotope in women with cervical carcinoma. Cancer 97:12, 3003-3009
CrossRef473
David M Brizel. (2003) Does amifostine have a role in chemoradiation treatment?. The Lancet Oncology 4:6, 378-380
CrossRef474
Henry M Keys, Brian N Bundy, Frederick B Stehman, Takashi Okagaki, Donald G Gallup, Alexander F Burnett, Marvin Z Rotman, Wesley C Fowler. (2003) Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group
. Gynecologic Oncology 89:3, 343-353
CrossRef475
Robert V Higgins, Wendel R Naumann, James B Hall, Michael Haake. (2003) Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecologic Oncology 89:3, 499-503
CrossRef476
Steven E Waggoner. (2003) Cervical cancer. The Lancet 361:9376, 2217-2225
CrossRef477
J Harney, K Goodchild, H Phillips, R Glynne-Jones, P.J Hoskin, M.I Saunders. (2003) A Phase I/II Study of CHARTWEL with Concurrent Chemotherapy in Locally Advanced, Inoperable Carcinoma of the Oesophagus. Clinical Oncology 15:3, 109-114
CrossRef478
Julie J Huh, Judith K Wolf, Diane L Fightmaster, Reuben Lotan, Michele Follen. (2003) Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells. Gynecologic Oncology 89:2, 243-250
CrossRef479
Brij M. Sood, Giridhar R. Gorla, Madhur Garg, Patrick S. Anderson, Abbie L. Fields, Carolyn D. Runowicz, Gary L. Goldberg, Bhadrasain Vikram. (2003) Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix. Cancer 97:7, 1781-1788
CrossRef480
Russell Hogg, Michael Friedlander. (2003) Role of systemic chemotherapy in metastatic cervical cancer. Expert Review of Anticancer Therapy 3:2, 234-240
CrossRef481
Chyong-Huey Lai, Kuan-Gen Huang, J.i-Hong Hong, Chyi-Long Lee, Hung-Hsueh Chou, Ting-Chang Chang, Swei Hsueh, Huei-Jean Huang, Koon-Kwan Ng, Chieh-Sheng Tsai. (2003) Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer
CrossRef482
Arthur Hung, Christopher Crane, Marc Delclos, Matthew Ballo, Jaffer Ajani, Edward Lin, Barry Feig, John Skibber, Nora Janjan. (2003) Cisplatin-based combined modality therapy for anal carcinoma. Cancer 97:5, 1195-1202
CrossRef483
H. -J. Huang, T. -C. Chang, J. -H. Hong, C. -J. Tseng, H. -H. Chou, K. -G. Huang, C. -H. Lai. (2003) Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky (>=4 cm) stage IB and IIA cervical carcinoma. International Journal of Gynecological Cancer 13:2, 204-211
CrossRef484
R. Yazigi, G. Aliste, R. Torres, A. M. Ciudad, M. Cuevas, J. Garrido, S. Prado, A. Sola, R. Castillo, B. Cerda, M. A. Cumsille, M. Gonzalez, C. Navarro, J. M. Reyes. (2003) Phase III randomized pilot study comparing interferon alpha- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix. International Journal of Gynecological Cancer 13:2, 164-169
CrossRef485
Sara C. Erridge, Nevin Murray. (2003) Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation. Seminars in Oncology 30:1, 26-37
CrossRef486
Achim Schneider, Lutz Gissmann. (2003) Cervical Cancer. American Journal of Cancer 2:4, 253-268
CrossRef487
R KIM, P PAREEK. (2003) Radiography-based treatment planning compared with computed tomography (CT)-based treatment planning for intracavitary brachytherapy in cancer of the cervix: Analysis of dose-volume histograms
CrossRef488
Claude Koren, Rinat Yerushalmi, Alan Katz, Hana Malik, Aaron Sulkes, Eyal Fenig. (2002) Hypersensitivity Reaction to Cisplatin During Chemoradiation Therapy for Gynecologic Malignancy. American Journal of Clinical Oncology 25:6, 625-626
CrossRef489
Syed A Hussain, Nicholas D James. (2002) Organ preservation strategies in bladder cancer. Expert Review of Anticancer Therapy 2:6, 641-651
CrossRef490
D HOLTZ, C DUNTON. (2002) Traditional management of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America 29:4, 645-657
CrossRef491
S IM, B MONK. (2002) New developments in the treatment of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America 29:4, 659-672
CrossRef492
Henry Kitchener. (2002) Evidence-based medicine applied to cervical cancer. Virus Research 89:2, 175-181
CrossRef493
Rachel Kupets, Gillian M. Thomas, Allan Covens. (2002) Is There a Role for Pelvic Lymph Node Debulking in Advanced Cervical Cancer?. Gynecologic Oncology 87:2, 163-170
CrossRef494
A.R. Munkarah, A. Jhingran, R.B. Iyer, S. Wallace, P.J. Eifel, D. Gershenson, T.W. Burke. (2002) Utility of lymphangiography in the prediction of lymph node metastases in patients with cervical cancer. International Journal of Gynecological Cancer 12:6, 755-759
CrossRef495
D.T. Rein, C.M. Kurbacher, M. Breidenbach, T. Schöndorf, T. Schmidt, E. König, U.-J. Göhring, J.-U. Blohmer, P. Mallmann. (2002) Weekly Carboplatin and Docetaxel for Locally Advanced Primary and Recurrent Cervical Cancer: A Phase I Study. Gynecologic Oncology 87:1, 98-103
CrossRef496
Tarik Belhocine, Alain Thille, Viviana Fridman, Adelin Albert, Laurence Seidel, Philippe Nickers, Frederic Kridelka, Pierre Rigo. (2002) Contribution of Whole-Body 18FDG PET Imaging in the Management of Cervical Cancer. Gynecologic Oncology 87:1, 90-97
CrossRef497
L. T. Soh, D. Heng, I. W. Lee, T. H. Ho, K. M. Hui. (2002) The relevance of oncogenes as prognostic markers in cervical cancer. International Journal of Gynecological Cancer 12:5, 465-474
CrossRef498
Panos T Lappas, Peter G Rose. (2002) Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a review. Expert Opinion on Pharmacotherapy 3:9, 1245-1249
CrossRef499
Christhardt Köhler, Roberto Tozzi, Marc Possover, Achim Schneider. (2002) Explorative Laparoscopy Prior to Exenterative Surgery. Gynecologic Oncology 86:3, 311-315
CrossRef500
P.O. Witteveen, M.J. Verhaar, I.M. Jürgenliemk-Schulz, M.A. van Eijkeren. (2002) Update on the treatment of advanced cervical cancer. Critical Reviews in Oncology/Hematology 43:3, 245-256
CrossRef501
B. M. Sood, P. F. Timmins, G. R. Gorla, M. Garg, P. S. Anderson, B. Vikram, G. L. Goldberg. (2002) Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer. International Journal of Gynecological Cancer 12:5, 459-464
CrossRef502
Yong Bae Kim, Gwi Eon Kim, Nam Hoon Cho, Hong Ryull Pyo, Su Jung Shim, Sei Kyung Chang, Hee Chul Park, Chang Ok Suh, Tchan Kyu Park, Byung Soo Kim. (2002) Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 95:3, 531-539
CrossRef503
A. Duenas-Gonzalez. (2002) Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. Annals of Oncology 13:8, 1212-1219
CrossRef504
H. Lukka, H. Hirte, A. Fyles, G. Thomas, L. Elit, M. Johnston, M. Fung Kee Fung, G. Browman. (2002) Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer–a Meta-analysis. Clinical Oncology 14:3, 203-212
CrossRef505
Liliana Vitali, J.Sebastian Yakisich, Marina Fernanda Vita, Alejandro Fernandez, Liliana Settembrini, Åke Siden, Mabel Cruz, Hector Carminatti, Oscar Casas, Victor Idoyaga Vargas. (2002) Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Letters 180:1, 7-12
CrossRef506
P. Symonds. (2002) Chemoradiation: The New Gold Standard For Non-Surgical Treatment Of Cervical Cancer. Clinical Oncology 14:3, 201-202
CrossRef507
K. Fujiwara, S. Suzuki, E. Yoden, H. Ishikawa, Y. Imajo, I. Kohno. (2002) Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. International Journal of Gynecological Cancer 12:3, 250-256
CrossRef508
Alexander D Guminski, Paul R Harnett, Anna deFazio. (2002) Scientists and clinicians test their metal–back to the future with platinum compounds. The Lancet Oncology 3:5, 312-318
CrossRef509
Dennis R. Scribner, Doris M. Benbrook. (2002) Retinoids Enhance Cisplatin-Based Chemoradiation in Cervical Cancer Cells in Vitro. Gynecologic Oncology 85:1, 223-225
CrossRef510
Charles J. Dunton, Stephanie A. King, Julia Neufeld, Jorge Tolosa, Gonzalo Perez, Andres Avila, Kelly Underhill. (2002) Phase I Study of Topotecan and Radiation Therapy in Advanced Cervical Cancer. Gynecologic Oncology 85:1, 185-187
CrossRef511
Stephanie V. Blank, Stephen C. Rubin, George Coukos, Kunjlata M. Amin, Steven M. Albelda, Katherine L. Molnar-Kimber. (2002) Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation. Human Gene Therapy 13:5, 627-639
CrossRef512
T. Uno, H. Ito, J. Itami, T. Sato, S. Minoura, S. Yasuda, T. Aruga, K. Isobe, N. Shigematsu, A. Kubo. (2002) Adjuvant pelvic irradiation in patients with pathologic T2b carcinoma of the uterine cervix. International Journal of Gynecological Cancer 12:2, 187-191
CrossRef513
Numa Cellini, Alessio G Morganti, Gabriella Macchia, Vincenzo Valentini, Stefano Luzi, Daniela Smaniotto. (2002) Chemoradiation in cervical carcinoma: a must?. Expert Review of Anticancer Therapy 2:1, 83-89
CrossRef514
Annette Hasenburg, Joseph K. Salama, T.John Van, Chad Amosson, J.Kam Chiu, Dirk G. Kieback. (2002) Evaluation of Patients after Extraperitoneal Lymph Node Dissection and Subsequent Radiotherapy for Cervical Cancer. Gynecologic Oncology 84:2, 321-326
CrossRef515
F. Foroudi, C.A. Bull, V. Gebski. (2002) Radiation Therapy for Cervix Carcinoma: Benefits of Individualized Dosimetry. Clinical Oncology 14:1, 43-49
CrossRef516
Yoichi Aoki, Kenichi Tanaka. (2002) Current approaches of neoadjuvant chemotherapy in cervical cancer. Expert Review of Anticancer Therapy 2:1, 73-82
CrossRef517
Jayanthi S. Lea, Ellen E. Sheets, Robert M. Wenham, Linda R. Duska, Robert L. Coleman, David S. Miller, John O. Schorge. (2002) Stage IIB–IVB Cervical Adenocarcinoma: Prognostic Factors and Survival. Gynecologic Oncology 84:1, 115-119
CrossRef518
Masahiro Sasaoka, Nobukazu Fuwa, Akiko Asano, Akira Matsumoto, Eriko Katou, Yoshiyuki Ito. (2001) Patterns of Failure in Carcinoma of the Uterine Cervix Treated With Definitive Radiotherapy Alone. American Journal of Clinical Oncology 24:6, 586-590
CrossRef519
J BASIL. (2001) CERVICAL CARCINOMAContemporary Management. Obstetrics and Gynecology Clinics of North America 28:4, 727-742
CrossRef520
Craig MacLeod, Anne O'Donnell, Martin HN Tattersall, Chris Dalrymple, Ian Firth. (2001) Locally advanced cervix cancer: Chemotherapy prior to definitive surgery or radiotherapy. A single institutional experience. Australasian Radiology 45:4, 491-495
CrossRef521
Hiroshi Tsuda, Masahiro Tanaka, Takao Manabe, Shinichi Nakata, Osamu Ishiko, Kumio Yamamoto. (2001) Phase I-II study of neoadjuvant chemoradiotherapy followed by radical surgery in locally advanced cervical cancer. Anti-Cancer Drugs 12:10, 853-858
CrossRef522
G. Scambia, G. Ferrandina, M. Distefano, A. Fagotti, R. Manfredi, G.F. Zannoni, S. Mancuso. (2001) Is There a Place for a Less Extensive Radical Surgery in Locally Advanced Cervical Cancer Patients?. Gynecologic Oncology 83:2, 319-324
CrossRef523
Daniel T Rein, Christian M Kurbacher. (2001) The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects. Anti-Cancer Drugs 12:10, 787-795
CrossRef524
J Green, J Kirwan, J Tierney, P Symonds, L Fresco, C Williams, M Collingwood. 2001. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. .
CrossRef525
A. Melcher. (2001) Chemoradiation: From the Laboratory to the Clinic*. Clinical Oncology 13:5, 356-360
CrossRef526
Michael Milosevic, Anthony Fyles, Richard Hill. (2001) Interstitial Fluid Pressure in Cervical Cancer. American Journal of Clinical Oncology 24:5, 516-521
CrossRef527
Arno J. Mundt, John C. Roeske, Anthony E. Lujan, S.Diane Yamada, Steve E. Waggoner, Gini Fleming, Jacob Rotmensch. (2001) Initial Clinical Experience with Intensity-Modulated Whole-Pelvis Radiation Therapy in Women with Gynecologic Malignancies. Gynecologic Oncology 82:3, 456-463
CrossRef528
John A Green, John M Kirwan, Jayne F Tierney, Paul Symonds, Lydia Fresco, Mandy Collingwood, Christopher J Williams. (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet 358:9284, 781-786
CrossRef529
PERRY W. GRIGSBY, THOMAS J. HERZOG. (2001) Current Management of Patients With Invasive Cervical Carcinoma. Clinical Obstetrics and Gynecology 44:3, 531-537
CrossRef530
Andreas Obermair, Robyn Cheuk, Keith Horwood, Monika Janda, Barbara Bachtiary, Barbara Schwanzelberger, Alexander Stoiber, James L. Nicklin, Lewis C. Perrin, Alex J. Crandon. (2001) Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma. Cancer 92:4, 903-908
CrossRef531
Rachel Kupets, Allan Covens. (2001) Is the International Federation of Gynecology and Obstetrics Staging System for Cervical Carcinoma able to predict survival in patients with cervical carcinoma?. Cancer 92:4, 796-804
CrossRef532
Rachelle Lanciano. (2001) OPTIMIZING RADIATION TREATMENT FOR CERVICAL CANCER. Surgical Clinics of North America 81:4, 859-870
CrossRef533
Bernd-Uwe Sevin, Ossi R. Koechli. (2001) PELVIC EXENTERATION. Surgical Clinics of North America 81:4, 771-779
CrossRef534
John D. Hainsworth, Howard A. Burris, Anthony A. Meluch, Margaret N. Baker, Lisa H. Morrissey, F. Anthony Greco. (2001) Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas. Cancer 92:3, 642-649
CrossRef535
Jacoba van der Zee, Curt W. Burger, Peter C. M. Koper. (2001) Comments on “Chemoradiation for Carcinoma of the Cervix: Advances and Opportunities” by Patricia Eifel ( Radiat. Res. 154, 229–236, 2000). Radiation Research 156:2, 221-222
CrossRef536
Arno J. Mundt, Jacob Rotmensch, Steven E. Waggoner, Diane Yamada, Sister Carole Langhauser, Gini F. Fleming. (2001) Phase I Trial of Concomitant Vinorelbine, Paclitaxel, and Pelvic Irradiation in Cervical Carcinoma and Other Advanced Pelvic Malignancies. Gynecologic Oncology 82:2, 333-337
CrossRef537
FH Gastrell, HD Brasch, CA Johnson, PB Bethwaite, DT McConnell. (2001) Malignant mixed Müllerian tumour of the cervix treated with concurrent chemoradiation. The Australian and New Zealand Journal of Obstetrics and Gynaecology 41:3, 352-354
CrossRef538
K. Narayan, R. J. Hicks, T. Jobling, D. Bernshaw, A. F. Mckenzie. (2001) A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: Potential impact on treatment. International Journal of Gynecological Cancer 11:4, 263-271
CrossRef539
Jacek Jassem. (2001) Combined chemotherapy and radiation in locally advanced nonsmall-cell lung cancer. The Lancet Oncology 2:6, 335-342
CrossRef540
P. Pattaranutaporn, C. Thirapakawong, Y. Chansilpa, S. Therasakvichya, N. Ieumwananontachai, K. Thephamongkhol. (2001) Phase II Study of Concurrent Gemcitabine and Radiotherapy in Locally Advanced Stage IIIB Cervical Carcinoma. Gynecologic Oncology 81:3, 404-407
CrossRef541
C. Lopez-Graniel, M. Reyes, G. Chanona, A. Gonzalez, E. Robles, A. Mohar, H. Lopez-Basave, J. G. De La Garza, A. Duenas-Gonzalez. (2001) Type III radical hysterectomy after induction chemotherapy for patients with locally advanced cervical carcinoma. International Journal of Gynecological Cancer 11:3, 210-217
CrossRef542
D.Scott McMeekin, Daphne Lashbrook, Michael Gold, Gary Johnson, Joan L. Walker, Robert Mannel. (2001) Analysis of FIGO Stage IIIc Endometrial Cancer Patients. Gynecologic Oncology 81:2, 273-278
CrossRef543
Brian D. Kavanagh, Eileen M. Segreti, Derrick Koo, Cyrus Amir, Douglas Arthur, John Wheelock, Robert M. Cardinale, Rupert K. Schmidt-Ullrich. (2001) Long-term Local Control and Survival After Concomitant Boost Accelerated Radiotherapy for Locally Advanced Cervix Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials 24:2, 113-119
CrossRef544
Nadeem R. Abu-Rustum, Suzette Lee, Arturo Correa, L.Stewart Massad. (2001) Compliance with and Acute Hematologic Toxic Effects of Chemoradiation in Indigent Women with Cervical Cancer. Gynecologic Oncology 81:1, 88-91
CrossRef545
Susan M. Ascher, Junko Takahama, Reena C. Jha. (2001) Staging of Gynecologic Malignancies. Topics in Magnetic Resonance Imaging 12:2, 105-129
CrossRef546
Erik A. Boss, Leon F.A.G. Massuger, Luc A.M. Pop, Lia C.G. Verhoef, Henk-Jan Huisman, Henk Boonstra, Jelle O. Barentsz. (2001) Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma. Journal of Magnetic Resonance Imaging 13:4, 600-606
CrossRef547
Benjamin Tham, Mahesh Parmar. (2001) Current and future trends in randomised trials in gynaecological oncology. The Obstetrician & Gynaecologist 3:2, 61-68
CrossRef548
Ronald J. Place, Sharon G. Gregorcyk, Philip J. Huber, Clifford L. Simmang. (2001) Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Diseases of the Colon & Rectum 44:4, 506-512
CrossRef549
Bruce D. Minsky. (2001) UFT
CrossRef550
Maria C. Bell, Susan A. Davidson, J.Michael Mathis, Federico Ampil. (2001) Topotecan Concomitant with Primary Brachytherapy Radiation in Patients with Cervical Carcinoma: A Phase I Trial. Gynecologic Oncology 80:2, 128-131
CrossRef551
Peter G. Rose. (2001) Locally advanced cervical cancer. Current Opinion in Obstetrics and Gynecology 13:1, 65-70
CrossRef552
Jan H. Schornagel, Marcel Verheij, Harry Bartelink. (2001) Concurrent chemotherapy and radiation for locally advanced squamous cell cancers: what is the schedule of choice?. Current Oncology Reports 3:1, 1-2
CrossRef553
Jeffrey D. Bloss. (2001) Chemotherapy for advanced or recurrent carcinoma of the cervix. Current Oncology Reports 3:1, 33-40
CrossRef554
John A. Stryker, Rodrigue Mortel. (2000) Survival Following Extended Field Irradiation in Carcinoma of Cervix Metastatic to Para-aortic Lymph Nodes. Gynecologic Oncology 79:3, 399-405
CrossRef555
Eng-Yen Huang, Hao Lin, Hsuan-Chih Hsu, Chong-Jong Wang, Hui-Chun Chen, Li-Min Sun, Ching-Yeh Hsiung. (2000) High External Parametrial Dose Can Increase the Probability of Radiation Proctitis in Patients with Uterine Cervix Cancer. Gynecologic Oncology 79:3, 406-410
CrossRef556
Marcela G. del Carmen, James F. McIntyre, Arlan F. Fuller, Najmosama Nikrui, Annekathryn Goodman. (2000) Intraoperative Radiation Therapy in the Treatment of Pelvic Gynecologic Malignancies: A Review of Fifteen Cases. Gynecologic Oncology 79:3, 457-462
CrossRef557
Peter G. Rose. (2000) Chemoradiotherapy. Drugs 60:6, 1239-1244
CrossRef558
Charles W. Whitney, Frederick B. Stehman. (2000) The Abandoned Radical Hysterectomy: A Gynecologic Oncology Group Study. Gynecologic Oncology 79:3, 350-356
CrossRef559
Walter Beerheide, Mui Mui Sim, Yee-Joo Tan, Hans-Ulrich Bernard, Anthony E Ting. (2000) Inactivation of the human papillomavirus-16 e6 oncoprotein by organic disulfides. Bioorganic & Medicinal Chemistry 8:11, 2549-2560
CrossRef560
Carlos T. Vallejo, Juan E. P??rez, Mar??a E. Dom??nguez, Bernardo A. Leone, Mario R. Machiavelli, Juan A. Lacava, Alberto O. Romero, Eduardo H. Ortiz, Sergio Grasso, Sonia Amato, Ricardo Rodr??guez, Mario Barbieri, Juan Romero Acu??a, Guillermo Focaccia, Guillermo Suttora, Mirna Scenna, Jos?? M. Boughen, Luis A. Romero Acu??a, Mario J. Langhi. (2000) Neoadjuvant Chemotherapy With Ifosfamide, Cisplatin, and Vinorelbine in Advanced Squamous Cell Carcinoma of the Cervix. American Journal of Clinical Oncology: Cancer Clinical Trials 23:5, 481-486
CrossRef561
Richard A. Britten, Dan Liu, Amy Tessier, Michael J. Hutchison, David Murray. (2000) ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. International Journal of Cancer 89:5, 453-457
CrossRef562
(2000) Guidelines for Referral to a Gynecologic Oncologist: Rationale and Benefits. Gynecologic Oncology 78:3, S1-S13
CrossRef563
Salvatore Mancuso, Daniela Smaniotto, Pierluigi Benedetti Panici, Barbara Favale, Stefano Greggi, Riccardo Manfredi, P.Alessandro Margariti, Alessio G. Morganti, Giovanni Scambia, Francesca Tortoreto, Vincenzo Valentini, Numa Cellini. (2000) Phase I–II Trial of Preoperative Chemoradiation in Locally Advanced Cervical Carcinoma. Gynecologic Oncology 78:3, 324-328
CrossRef564
Patricia J. Eifel. (2000) Chemoradiation for Carcinoma of the Cervix: Advances and Opportunities. Radiation Research 154:3, 229-236
CrossRef565
Kenneth B. Roberts, Nelson Urdaneta, Raul Vera, Andres Vera, Enrique Gutierrez, Yadelis Aguilar, Sara Ott, Ivonne Medina, Pilar Sempere, Sara Rockwell, Alan C. Sartorelli, Diana B. Fischer, James J. Fischer. (2000) Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. International Journal of Cancer 90:4, 206-223
CrossRef566
J VERWEIJ, M DEJONGE. (2000) Achievements and future of chemotherapy. European Journal of Cancer 36:12, 1479-1487
CrossRef567
Craig McLeod, Philip Beale, Martin Tattersall, Chris Dalrymple, Ken Atkinson, Jonathon Carter. (2000) Early results of chemo-radiotherapy for the definitive treatment of cervix cancer. The Australian and New Zealand Journal of Obstetrics and Gynaecology 40:3, 341-342
CrossRef568
Enrique Hernandez, Kathleen A. Donohue, Lisa L. Anderson, Paul B. Heller, Frederick B. Stehman. (2000) The Significance of Thrombocytosis in Patients with Locally Advanced Cervical Carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology 78:2, 137-142
CrossRef569
Peter G Rose, Panos T Lappas. (2000) Analysis of the Cost Effectiveness of Concurrent Cisplatin-Based Chemoradiation in Cervical Cancer: Implications from Five Randomized Trials. Gynecologic Oncology 78:1, 3-6
CrossRef570
Laurie Elit, Amiram Gafni, Mark N. Levine. (2000) Better Treatments That Cost More: The Dilemma. Gynecologic Oncology 78:1, 1-2
CrossRef571
Ruud E. van Rijswijk, Jan B. Vermorken. (2000) Drug Therapy for Gynaecological Cancer in Older Women. Drugs & Aging 17:1, 13-32
CrossRef572
P. Morice, C. Haie-Meder, A. Rey, P. Pautier, C. Lhomme, A. Gerbaulet, P. Duvillard, D. Castaigne. (2000) Radiotherapy and radical surgery for treatment of patients with bulky stage IB and II cervical carcinoma. International Journal of Gynecological Cancer 10:3, 239-246
CrossRef573
R Symonds. (2000) The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. European Journal of Cancer 36:8, 994-1001
CrossRef574
Xiang Gao. (2000) Adjuvant Chemotherapy or Radiotherapy in Cervical Cancer. Gynecologic Oncology 77:2, 340-341
CrossRef575
Yoichi Aoki, Masaru Sasaki, Minoru Watanabe, Takaaki Sato, Ikunosuke Tsuneki, Hiroshi Aida, Kenichi Tanaka. (2000) High-Risk Group in Node-Positive Patients with Stage IB, IIA, and IIB Cervical Carcinoma after Radical Hysterectomy and Postoperative Pelvic Irradiation. Gynecologic Oncology 77:2, 305-309
CrossRef576
Susan K. Gibbons, Henry M. Keys. (2000) Advanced cervical cancer. Current Treatment Options in Oncology 1:2, 157-160
CrossRef577
Merideth C. Kamradt, Najeeb Mohideen, Andrew T.M. Vaughan. (2000) RU486 Increases Radiosensitivity and Restores Apoptosis through Modulation of HPV E6/E7 in Dexamethasone-Treated Cervical Carcinoma Cells. Gynecologic Oncology 77:1, 177-182
CrossRef578
Paul J. M. van de Vaart, Jose Belderbos, Daphne de Jong, Kommer C.A. Sneeuw, Donne Majoor, Harry Bartelink, Adrian C. Begg. (2000) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. International Journal of Cancer 89:2, 160-166
CrossRef579
A Uitterhoeve. (2000) Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer results of the EORTC 08912 phase I/II study. European Journal of Cancer 36:5, 592-600
CrossRef580
Y NAGATA, N ARAKI, H KIMURA, K FUJIWARA, K OKAJIMA, T AOKI, M MITSUMORI, K SASAI, M HIRAOKA, T HIGUCHI. (2000) Neoadjuvant Chemotherapy by Transcatheter Arterial Infusion Method for Uterine Cervical Cancer. Journal of Vascular and Interventional Radiology 11:3, 313-319
CrossRef581
Michael E. Hagensee. (2000) Infection with human papillomavirus: Update on epidemiology, diagnosis, and treatment. Current Infectious Disease Reports 2:1, 18-24
CrossRef582
Srdan Verstovsek, Claire F. Verschraegen, Creighton L. Edwards, Anais Malpica, John J. Kavanagh, Merrick I. Ross, Eric A. Strom, Anuja Jhingran, Richard L. Theriault, Andrzej P. Kudelka. (2000) Synchronous Primary Cancers of the Breast and Cervix: Planning Multidisciplinary Primary Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials 23:1, 99
CrossRef583
Hiroyoshi Yuki, Masaki Fujimura, Yoshihiro Yamakawa, Takao Hidaka, Shigeru Saito. (2000) Detection of Apoptosis and Expression of Apoptosis-associated Proteins as Early Predictors of Prognosis after Irradiation Therapy in Stage IIIb Uterine Cervical Cancer. Cancer Science 91:1, 127-134
CrossRef584
Benjamin Piura, Alex Rabinovich, Mihai Meirovitz, Ilana Yanai-Inbar. (1999) Glassy cell carcinoma of the uterine cervix. Journal of Surgical Oncology 72:4, 206-210
CrossRef585
N.S. Russell, H. Bartelink. (1999) Radiotherapy: the last 25 years. Cancer Treatment Reviews 25:6, 365-376
CrossRef586
R.P. Symonds. (1999) Concurrent chemotherapy and radiotherapy: An affordable important improvement in the treatment of advanced cervical cancer. Medical and Pediatric Oncology 33:5, 493-496
CrossRef587
R. J. Cardosi, M. B. Reedy, J. R. Van Nagell, S. E. Spires. (1999) Neuroendocrine signet ring cell adenocarcinoma of the endocervix. International Journal of Gynecological Cancer 9:5, 433-437
CrossRef588
Sandra E. Brooks, Katie E. Wakeley. (1999) Current trends in the management of carcinoma of the cervix, vulva, and vagina. Current Opinion in Oncology 11:5, 383
CrossRef589
(1999) Treatment of High-Risk Cervical Cancer. New England Journal of Medicine 341:9, 695-697
Full Text590
A. Duenas-Gonzalez, F. U. Lara-Medina, G. Solorza-Luna, A. Mota-Garcia, J. De la garza-Salazar, P. J. Sobrevilla-Calvo. (1999) Adjuvant high-dose chemotherapy supported by peripheral blood stem cell transplantation for high-risk cervical carcinoma. International Journal of Gynecological Cancer 9:4, 333-336
CrossRef591
Jürgen Dunst, Rolf Sauer. (1999) Simultane radiochemotherapie mit cisplatin verbessert überleben bei patientinnen mit zervixkarzinom. Strahlentherapie und Onkologie 175:6, 257-258
CrossRef592
Thomas, Gillian M., . (1999) Improved Treatment for Cervical Cancer — Concurrent Chemotherapy and Radiotherapy. New England Journal of Medicine 340:15, 1198-1200
Full Text593
Keys, Henry M., Bundy, Brian N., Stehman, Frederick B., Muderspach, Laila I., Chafe, Weldon E., Suggs, Charles L., Walker, Joan L., Gersell, Deborah, . (1999) Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma. New England Journal of Medicine 340:15, 1154-1161
Full Text594
Jeanne M. Schilder, Frederick B. Stehman. (1999) Concurrent chemotherapy and radiation therapy in primary cancer of the cervix. Current Oncology Reports 1:1, 41-46
CrossRef595
Ihn Han, Colin Orton, Falah Shamsa, Kim Hart, Amy Strowbridge, Gunter Deppe, Arthur Porter, Paul J. Chuba. (1999) Combined low-dose-rate brachytherapy and external beam radiation for cervical cancer:Experience over ten years. Radiation Oncology Investigations 7:5, 289-296
CrossRef
